

10615126amend

FILE 'REGISTRY' ENTERED AT 14:28:06 ON 21 MAR 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 20 MAR 2006 HIGHEST RN 877371-73-8
DICTIONARY FILE UPDATES: 20 MAR 2006 HIGHEST RN 877371-73-8

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 6, 2006

Please note that search-term pricing does apply when conducting SmartSELECT searches.



```
*****
* The CA roles and document type information have been removed from *
* the IDE default display format and the ED field has been added,   *
* effective March 20, 2005. A new display format, IDERL, is now      *
* available and contains the CA role and document type information. *
*****
```

Structure search iteration limits have been increased. See HELP SLIMITS for details.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/regprops.html>

=>
Uploading C:\Program Files\Stnexp\Queries\10615126amend2.str



chain nodes :
16 18 20 23

10615126amend

ring nodes :
1 2 3 4 5 6 7 8 9 10 11 12 13 14
chain bonds :
7-18 12-23 13-20
ring bonds :
1-2 1-6 1-10 2-3 3-4 4-5 5-6 6-7 7-8 7-11 8-9 8-14 9-10 11-12 12-13 13-14
exact/norm bonds :
1-10 6-7 7-8 7-11 7-18 8-9 8-14 9-10 11-12 12-13 12-23 13-14 13-20
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6

G1:X,Ak,H

G2:Ak,Ph


G3:N,OH

G4:Cy,Ak

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom 11:Atom
12:Atom 13:Atom 14:Atom 16:CLASS 17:CLASS 18:CLASS 20:CLASS 23:CLASS

L9 STRUCTURE UPLOADED

=> d 19
L9 HAS NO ANSWERS
L9 STR



G1 X,Ak,H

G2 Ak,Ph

G3 N,OH

G4 Cy,Ak

Structure attributes must be viewed using STN Express query preparation.

=> s 19
SAMPLE SEARCH INITIATED 14:29:13 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 15855 TO ITERATE

12.6% PROCESSED 2000 ITERATIONS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)

1 ANSWERS

10615126amend

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 309559 TO 324641
PROJECTED ANSWERS: 1 TO 326

L10 1 SEA SSS SAM L9

=> s 19 full
FULL SEARCH INITIATED 14:29:18 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 315891 TO ITERATE

100.0% PROCESSED 315891 ITERATIONS 156 ANSWERS
SEARCH TIME: 00.00.06

L11 156 SEA SSS FUL L9

=> fil hcplus
COST IN U.S. DOLLARS SINCE FILE TOTAL
ENTRY SESSION
FULL ESTIMATED COST 167.38 754.20
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS) SINCE FILE TOTAL
ENTRY SESSION
CA SUBSCRIBER PRICE 0.00 -32.25

FILE 'HCAPLUS' ENTERED AT 14:29:29 ON 21 MAR 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 21 Mar 2006 VOL 144 ISS 13
FILE LAST UPDATED: 20 Mar 2006 (20060320/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s 111
L12 15 L11

=> d ed abs ibib hitstr 1-15

L12 ANSWER 1 OF 15 HCAPLUS COPYRIGHT 2006 ACS on STN
 ED Entered STN: 27 May 2005
 GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The invention relates to a preparation of octahydrophenanthrenecarboxylic acid hydrazide derivs. of formula I [wherein: R1 is 1 to 6 independent substituents; R2 is 1 or 2 independent substituents selected from H, alkyl optionally substituted with 1-3 halogens, alkyanyl, or OH, etc.; R3 is heterocycle], useful as glucocorticoid receptor modulators. The invention compds. are useful in the treatment of obesity, diabetes, anxiety, or inflammatory diseases. For instance, octahydrophenanthrenecarboxylic acid hydrazide derivative II was prepared from naphthalene derivative III in 9 steps.

Preferred invention compds. showed ED50 less than 3 μ M.

ACCESSION NUMBER: 20051451357 HCAPLUS

DOCUMENT NUMBER: 143:7512

TITLE: A preparation of octahydrophenanthrenecarboxylic acid hydrazide derivatives, useful as glucocorticoid receptor modulators

INVENTOR(S): Robinson, Ralph Pelton, Jr.; Kleinman, Edward Fox;

CHENG, Hengmiao; Pfizer Products Inc., USA

SOURCE: PCT Int. Appl., 44 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005047254	A1	20050526	WO 2004-IB3671	20041108
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, C2, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, 2M, 2W, AM, A2, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				

PRIORITY APPLN. INFO.: US 2003-519937P P 20031113

OTHER SOURCE(S): MARPAT 143:7512

IT 852403-63-5P

RL: PAC (pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (biological study); PREP (Preparation); USES (Uses)


(preparation of octahydrophenanthrenecarboxylic acid hydrazide derivs. useful as glucocorticoid receptor modulators)

RN 852403-63-5 HCAPLUS

CN 2-Phenanthrenecarboxylic acid, 4b-ethyl-4b,5,6,7,8,8a,9,10-octahydro-6,7-dihydroxy-6-methyl-7-(2-thiazolyl)-, 2-(2-pyridinyl)hydrazide,

L12 ANSWER 1 OF 15 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 (4bR,6R,7R,8aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 645398-33-0P 852403-64-6P 852403-65-7P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of octahydrophenanthrenecarboxylic acid hydrazide derivs. useful as glucocorticoid receptor modulators)

RN 645398-33-0 HCAPLUS

CN 2,3,7-Phenanthrenetriol, 4a-ethyl-1,2,3,4,4a,9,10,10a-octahydro-3-methyl-2-(2-thiazolyl)-, 7-methanesulfonate, (2R,3R,4aR,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 852403-64-6 HCAPLUS

CN 2,3,7-Phenanthrenetriol, 4a-ethyl-1,2,3,4,4a,9,10,10a-octahydro-3-methyl-2-(2-thiazolyl)-, 7-methanesulfonate, (2R,3R,4aR,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L12 ANSWER 1 OF 15 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 852403-65-7 HCAPLUS

CN 2-Phenanthrenecarboxylic acid, 4b-ethyl-4b,5,6,7,8,8a,9,10-octahydro-6,7-dihydroxy-6-methyl-7-(2-thiazolyl)-, methyl ester, (4bR,6R,7R,8aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 852403-66-8 HCAPLUS


CN 2-Phenanthrenecarboxylic acid, 4b-ethyl-4b,5,6,7,8,8a,9,10-octahydro-6,7-dihydroxy-6-methyl-7-(2-thiazolyl)-, (4bR,6R,7R,8aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 2 OF 15 HCAPLUS COPYRIGHT 2006 ACS on STN
 ED Entered STN: 26 Apr 2004
 GI



AB A rhodium-catalyzed alkyne cyclotrimerization, domino electrocyclic reactions, and a hydroxy-directed dihydroxylation are key steps in an efficient synthesis of the bioactive furanosteroid (*±*)-viridin (I) from a simple acyclic triyne.

ACCESSION NUMBER: 2004335521 HCAPLUS

DOCUMENT NUMBER: 141:38766

TITLE: Synthesis of the furanosteroidal antibiotic viridin
 ANDERSON, Edward A.; Alexanian, Erik J.; Sorensen, Erik J.

CORPORATE SOURCE: Department of Chemistry and The Skaggs Institute for Chemical Biology, The Scripps Research Institute, La Jolla, CA, 92037, USA

SOURCE: Angewandte Chemie, International Edition (2004), 43(15), 1998-2001

CODEN: ACIEF5; ISSN: 1433-7851

PUBLISHER: Wiley-VCH Verlag GmbH & Co. KGaA

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 141:38766


IT 700869-36-9P 700869-45-0P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(synthesis of (*±*)-viridin via cyclotrimerization, electrocyclic rearrangement and dihydroxylation)

RN 700869-36-9 HCAPLUS


CN 18-Norandrosta-5,8,11,13-tetraeno[6,5,4-bc]furan-7-one, 17-[(1,1-dimethylethyl)dimethylsilyl]oxy-1,2,3-trihydroxy-, (1B,2B,3B)- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 700869-45-0 HCAPLUS
 CN 18-Norandrosta-5,8,11,13-tetraeno[6,5,4-bc]furan-7-one, 17-[(1,1-dimethylethyl)dimethylsilyloxy]-1-(1-ethoxyethoxy)-2,3-dihydroxy-, (1B,2B,3B)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



REFERENCE COUNT: 48 THERE ARE 48 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT



AB Two new erythroxylane diterpenes, named givotin A (I) and givotin B (II) were isolated from the bark of *Givotia madagascariensis*. Their structures have been established as 3a,12a-dihydroxy-4(19),15-erythroxyladiene and 3a-hydroxy-4(19),15-erythroxyladiene, resp., on the basis of one and two-dimensional NMR spectroscopic studies (1H, 13C, COSY, HMQC, HMBC, NOESY, NOE difference spectra) as well as on mass spectral anal. In addition six known compds. have been isolated and identified. Cleistostanol, spruceanol and 1,2-dihydrodeudelocinol demonstrated significant antitumor activities against three tumor cell lines (HNO2, Hep G2, MCF7).

ACCESSION NUMBER: 2004:279259 HCAPLUS

DOCUMENT NUMBER: 141:103166

TITLE: Chemical composition and antitumor activities from *Givotia madagascariensis*

AUTHOR(S): Krebs, Hans C.; Duddack, Helmut; Malik, Shahid; Beil, Wulf; Raschauvo, Philippe; Andrianarivo, Mamy

CORPORATE SOURCE: Zentrum fuer Lebmittelwissenschaften, ZA fuer Chetische Analytik und Endokrinologie, Tiersaerztliche Hochschule Hannover, Hannover, D-30173, Germany

SOURCE: Zeitschrift fuer Naturforschung, B: Chemical Sciences (2004) 59(1), 58-62

PUBLISHER: Verlag der Zeitschrift fuer Naturforschung

DOCUMENT TYPE: Journal

LANGUAGE: English


IT 24465-21-2, Cleistostanol

RL: BEU (Biological study, unclassified); PAC (Pharmacological activity); BIOL (Biological study) (composition and antitumor activities from *Givotia madagascariensis*)



RN 24465-21-2 HCAPLUS

CN 2,3,6-Phenanthrenetriol, 8-ethenyl-1,2,3,4,4a,9,10,10a-octahydro-1,1a,4a,7-tetramethyl-, (2S,3R,4aR,10aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 14 THERE ARE 14 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT



Agapal

AB Title compds. I [wherein A = CR6R7CR8R9, COCR10R11, or CR12=CR13; X and Y = independently H, F, Cl, Br, or alkyl; R1 = alkyl, alkenyl, or (un)substituted benzyl; R2 = (un)substituted (cyclo)alkyl(alkyl), alkenyl, alkynyl, (hetero)aryl(alkyl), or heterocyclyl(alkyl); R3 = H or (un)substituted (cyclo)alkyl, alkenyl, alkynyl, heterocyclyl, or (hetero)aryl; R4 = OH or NR14R15; R5 = H, halo, OH, CN, or (un)substituted (cyclo)alkyl(oxy), alkenyl, alkynyl, (hetero)aryl(oxy), heterocyclyl(oxy), carbamoyl, sulfamoyl, acyl(oxy), etc.; R6-R9 = independently H, alkyl, F, or OH; R10 and R11 = independently H or alkyl; R12 and R13 = independently H, F, or alkyl; R14 and R15 = independently H or alkyl; and pharmaceutically acceptable salts thereof] were prepared as glucocorticoid receptor agonists (no data). For example, (3S,4aR,10aR)-3-bromo-4-*a*-ethyl-7-hydroxy-3,4,4a,9,10,10a-hexahydro-1*H*-phenanthren-2-one (multi-step preparation given) was treated with NaOH in DMF and H2O followed by 0.2M HCl to give a 2:1 mixture of the 2-keto-3-hydroxy and 2-hydroxy-3-keto derivs. The 2-keto-enriched compound (9:1 ratio of 2-keto to 3-keto derivative) was alkylated with propyne in THF using BuLi in hexane to afford II (25%). Bioassays for glucocorticoid receptor modulation and antiinflammatory responses are described, but no specific data are provided. Thus, I and their pharmaceutical compds., salts, and prodrugs are useful in the treatment of certain inflammatory disorders, endocrine disorders, collagen diseases, dermatol. diseases, allergic states, ophthalmic diseases, respiratory diseases, hematol. disorders, neoplastic diseases, edematous states, and gastrointestinal diseases (no data).

ACCESSION NUMBER: 2004:41424 HCAPLUS

DOCUMENT NUMBER: 140:111136

TITLE: Preparation of octahydrophenanthrenols as glucocorticoid receptor modulators for treatment of inflammatory conditions

INVENTOR(S): Chantigny, Yves Andre; Kleinman, Edward Fox; Robinson, Ralph Pelton, Jr.

PATENT ASSIGNEE(S): Pfizer Products Inc., USA

SOURCE: PCT Int. Appl., 143 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

L12 ANSWER 4 OF 15 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004005229	A1	20040115	WO 2003-IB2941	20030625
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DS, EC, EE, ES, FI, GB, GD, GE, GH, GR, HR, HU, ID, IL, IS, JP, KE, KG, KP, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MG, MK, MD, MM, MO, MD, NI, NO, NZ, OH, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SI, TJ, TM, TN, TR, TW, TZ, UA, UC, UZ, VC, VN, YU, ZA, BM, BN				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UC, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, ES, ES, FI, FR, GB, GR, HU, IL, IT, LU, MG, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GO, GM, ML, MR, NE, SN, TD, TG				
CA 2491994	AA	20040115	CA 2003-2491994	20030625
AU 2003281355	A1	20040123	AU 2003-2481355	20030625
EP 1521733	A1	20050413	EP 2003-740911	20030625
R: AT, BE, CH, DE, DK, ES, FR, GB, GE, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TZ, BG, CZ, EE, HU, SK				
BR 2003012575	A	20050503	BR 2003-12575	20030625
JP 2005532389	T2	20051027	JP 2004-519100	20030625
US 2004138262	A1	20040715	US 2003-615126	20030708

PRIORITY APPLN. INFO.: P 2002-394425P P 20020708
 WO 2003-IB2941 W 20030625


OTHER SOURCE(S): MARPAT 140:111136

IT 645397-31-59 HCAPLUS
 645397-45-18 HCAPLUS
 645397-52-08, (6S,7R,8aR)-4b-Ethyl-6,7-dihydroxy-7-prop-1-ynyl-4b,5,6,7,8,8a,9,10-octahydrophenanthrene-2-carbonitrile
 645397-55-39 (445397-59-78) HCAPLUS
 645397-62-28 HCAPLUS
 645397-64-48 HCAPLUS
 645397-62-69 HCAPLUS
 645397-63-79 HCAPLUS
 645397-64-09 HCAPLUS
 645397-65-99 HCAPLUS
 645397-66-09 HCAPLUS
 645397-18-1P HCAPLUS
 645397-69-39 HCAPLUS
 645398-25-09 HCAPLUS
 645398-29-48, (2R,3R,4aR,10aS)-4a-Ethyl-2,3,7-trihydroxy-3-methyl-2-oxopyridin-2-yl)-2,3,4,4a,10,10a-hexahydro-1H-phenanthren-9-one
 645398-39-69 HCAPLUS
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses); (glucocorticoid receptor modulator; preparation of octahydrophenanthrenols as glucocorticoid receptor modulators for treatment of inflammatory conditions)

RN 645397-31-5 HCAPLUS
 CN 2,3,7-Phenanthrenetriol, 4a-ethyl-1,2,3,4a,9,10,10a-octahydro-2-phenyl-, (2R,3S,4aR,10aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L12 ANSWER 4 OF 15 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 645397-45-1 HCAPLUS
 CN 2,3,7-Phenanthrenetriol, 4a-ethyl-2-(4-fluorophenyl)-1,2,3,4a,9,10,10a-octahydro-, (2R,3S,4aR,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 645397-47-3 HCAPLUS
 CN 2,3,7-Phenanthrenetriol, 1,2,3,4,4a,9,10,10a-octahydro-2-phenyl-4a-(phenylmethyl)-, (2R,3S,4aR,10aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 645397-52-0 HCAPLUS
 CN 2-Phenanthrenecarbonitrile, 4b-ethyl-4b,5,6,7,8,8a,9,10-octahydro-6,7-dihydroxy-7-(1-propynyl)-, (4bR,6S,7R,8aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L12 ANSWER 4 OF 15 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 645397-55-3 HCAPLUS
 CN 2,3,7-Phenanthrenetriol, 2-(2,6-difluorophenyl)-4a-ethyl-1,2,3,4a,9,10,10a-octahydro-, (2R,3S,4aR,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 645397-59-7 HCAPLUS
 CN 2,3,7-Phenanthrenetriol, 4a-ethyl-1,2,3,4a,9,10,10a-octahydro-2-phenyl-, (2R,3S,4aR,9R,10aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 645397-62-2 HCAPLUS
 CN 2,3,7-Phenanthrenetriol, 4a-ethyl-1,2,3,4a,9,10,10a-octahydro-3-methyl-2-phenyl-, (2R,3R,4aR,10aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L12 ANSWER 4 OF 15 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 645397-64-4 HCAPLUS
 CN 9(1H)-Phenanthrenone, 4a-ethyl-2,3,4,4a,10,10a-hexahydro-2,3,7-trihydroxy-3-methyl-2-phenyl-, (2R,3R,4aR,10aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 645397-82-6 HCAPLUS
 CN Acetic acid, [(4bR,6R,7R,8aR)-4b-ethyl-4b,5,6,7,8,8a,9,10-octahydro-6,7-dihydroxy-6-methyl-7-phenyl-2-phenanthrenyloxy]-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 645397-83-7 HCAPLUS
 CN Butanoic acid, 4-[(4bR,6R,7R,8aR)-4b-ethyl-4b,5,6,7,8,8a,9,10-octahydro-6,7-dihydroxy-6-methyl-7-phenyl-2-phenanthrenyloxy]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 645397-84-8 HCPLUS
 CN Pentanoic acid, 5-[(4bR,6R,7R,8aR)-4b-ethyl-4b,5,6,7,8,8a,9,10-octahydro-6,7-dihydroxy-6-methyl-7-phenyl-2-phenanthrenyl]oxy-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 645397-85-9 HCPLUS
 CN Acetonitrile, [(4bR,6R,7R,8aR)-4b-ethyl-4b,5,6,7,8,8a,9,10-octahydro-6,7-dihydroxy-6-methyl-7-phenyl-2-phenanthrenyl]oxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 645397-86-0 HCPLUS
 CN Butanenitrile, 4-[(4bR,6R,7R,8aR)-4b-ethyl-4b,5,6,7,8,8a,9,10-octahydro-6,7-dihydroxy-6-methyl-7-phenyl-2-phenanthrenyl]oxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 645398-29-4 HCPLUS
 CN 9(1H)-Phenanthrenone, 4-ethyl-2,3,4,4a,10,10a-hexahydro-2,3,7-trihydroxy-3-methyl-2-(2-pyridinyl)- (2R,3R,4aR,10aS) (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 645398-39-6 HCPLUS
 CN Ethanone, 1-[(4bR,6R,7R,8aR)-4b-ethyl-4b,5,6,7,8,8a,9,10-octahydro-6,7-dihydroxy-6-methyl-7-phenyl-2-phenanthrenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 645397-13-3P, (2R,3S,4aR,10aR)-4a-Ethyl-2-prop-1-ynyl-1,2,3,4,4a,9,10,10a-octahydrophenanthrene-2,3,7-triol 645397-14-4P , (2R,3S,4aR,10aR)-4a-Ethyl-7-[(2-methylpyridin-3-yl)methyl]oxy-2-(prop-1-ynyl)-1,2,3,4,4a,9,10,10a-octahydrophenanthrene-2,3-diol 645397-15-5P , (2R,3S,4aR,10aR)-4a-Ethyl-2-prop-1-ynyl-7-[(pyridin-2-yl)methoxy]-1,2,3,4,4a,9,10,10a-octahydrophenanthrene-2,3-diol 645397-16-6P , (2R,3S,4aR,10aR)-4a-Ethyl-2-prop-1-ynyl-7-[(2,4-Dimethylpyridin-3-yl)methyl]oxy-4a-ethyl-2-prop-1-ynyl-1,2,3,4,4a,9,10,10a-




RN 645397-87-1 HCPLUS
 CN Pentanenitrile, 5-[(4bR,6R,7R,8aR)-4b-ethyl-4b,5,6,7,8,8a,9,10-octahydro-6,7-dihydroxy-6-methyl-7-phenyl-2-phenanthrenyl]oxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 645397-89-3 HCPLUS
 CN Acetic acid, [(4bR,6R,7R,8aR)-4b-ethyl-4b,5,6,7,8,8a,9,10-octahydro-6,7-dihydroxy-6-methyl-7-phenyl-2-phenanthrenyl]oxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 645398-25-0 HCPLUS
 CN Acetonitrile, [(4bR,6R,7R,8aR)-4b-ethyl-4b,5,6,7,8,8a,9,10-octahydro-6,7-dihydroxy-6-methyl-7-(2-pyridinyl)-2-phenanthrenyl]oxy- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

octahydrophenanthrene-2,3-diol 645397-18-8P , (2R,3S,4aR,10aR)-4a-Ethyl-2-prop-1-ynyl-7-[(pyridin-3-yl)methoxy]-1,2,3,4,4a,9,10,10a-octahydrophenanthrene-2,3-diol 645397-19-9P , (2R,3S,4aR,10aR)-4a-Ethyl-7-[(6-methylpyridin-3-yl)methyl]oxy-2-prop-1-ynyl-1,2,3,4,4a,9,10,10a-octahydrophenanthrene-2,3-diol 645397-20-2P , (2R,3S,4aR,10aR)-7-[(5-[(Diethylamino)methyl]-1,2,4-oxadiazol-3-yl)methyl]oxy-4a-ethyl-2-prop-1-ynyl-1,2,3,4,4a,9,10,10a-octahydrophenanthrene-2,3-diol 645397-23-5P 645397-24-6P , (2S,3S,4aR,10aR)-2-Butyl-4a-ethyl-1,2,3,4,4a,9,10,10a-octahydrophenanthrene-2,3,7-triol 645397-25-7P , (2R,3S,4aR,10aR)-2-Butyl-4a-ethyl-1,2,3,4,4a,9,10,10a-octahydrophenanthrene-2,3,7-triol 645397-26-8P 645397-27-9P 645397-28-0P 645397-29-1P 645397-30-4P , (2R,3S,4aR,10aR)-4a-Ethyl-2-trifluoromethyl-1,2,3,4,4a,9,10,10a-octahydrophenanthrene-2,3,7-triol 645397-32-6P 645397-33-7P 645397-34-8P 645397-35-9P 645397-36-0P , (2R,3S,4aR,10aR)-2-Benzyl-4a-ethyl-1,2,3,4,4a,9,10,10a-octahydrophenanthrene-2,3,7-triol 645397-37-1P , (2R,3S,4aR,10aR)-2-Benzyl-4a-ethyl-1,2,3,4,4a,9,10,10a-octahydrophenanthrene-2,3,7-triol 645397-38-2P 645397-39-3P , (2R,3S,4aR,10aR)-4a-allyl-2-benzyl-1,2,3,4,4a,9,10,10a-octahydrophenanthrene-2,3,7-triol 645397-39-3P , (2R,3S,4aR,10aR)-4a-allyl-2-benzyl-1,2,3,4,4a,9,10,10a-octahydrophenanthrene-2,3,7-triol 645397-40-6P 645397-41-7P 645397-42-8P 645397-46-2P 645397-50-8P 645397-51-9P 645397-53-1P , (6S,7R,8R,9R,10aR)-4a-Ethyl-6,7-dihydroxy-7-prop-1-ynyl-4b,5,6,7,8,8a,9,10-octahydrophenanthrene-2-carboxylic acid N-[(2-methylpyridin-3-yl)methyl]amide 645397-56-4P 645397-57-5P

645397-58-6P 645397-60-0P 645397-61-1P 645397-63-3P 645397-65-5P 645397-66-6P 645397-67-7P 645397-68-8P 645397-69-9P 645397-70-2P 645397-71-3P 645397-72-4P 645397-73-5P 645397-74-6P 645397-75-7P 645397-76-8P 645397-77-9P 645397-78-0P 645397-79-1P 645397-80-4P 645397-81-5P 645397-88-2P 645397-90-6P 645397-91-7P 645397-92-9P 645397-93-9P 645397-94-0P 645397-95-1P 645397-96-2P 645397-97-3P 645397-98-4P 645397-99-5P 645398-00-1P 645398-01-2P 645398-02-3P 645398-03-4P 645398-04-5P 645398-05-6P 645398-06-7P 645398-07-8P 645398-08-9P 645398-09-0P 645398-10-3P 645398-11-4P 645398-12-5P 645398-13-6P 645398-14-7P 645398-15-8P 645398-16-9P 645398-17-0P 645398-18-1P , (2R,3S,4aR,10aR)-4a-Ethyl-3-methyl-2-(pyridin-2-yl)-1,2,3,4,4a,9,10,10a-octahydrophenanthrene-2,3,7-triol 645398-19-2P 645398-21-6P 645398-23-8P , (2R,3S,4aR,10aR)-4a-Ethyl-3-methyl-7-[(2-methylpyridin-3-yl)methyl]oxy-2-(pyridin-2-yl)-1,2,3,4,4a,9,10,10a-octahydrophenanthrene-2,3-diol 645398-24-9P 645398-26-1P , (2R,3S,4aR,10aR)-7-[(5-(2-Azetidin-1-yl)ethyl)-1,2,4-oxadiazol-3-yl)methyl]oxy-4a-ethyl-3-methyl-2-(pyridin-2-yl)-1,2,3,4,4a,9,10,10a-octahydrophenanthrene-2,3-diol 645398-27-2P 645398-28-3P , (1,2,4-oxadiazol-3-yl)methyl]oxy-4a-ethyl-3-methyl-2-(pyridin-2-yl)-1,2,3,4,4a,9,10,10a-octahydrophenanthrene-2,3-diol 645398-30-7P 645398-31-8P , (2R,3S,4aR,10aR)-4a-Ethyl-2-(pyridin-2-yl)-1,2,3,4,4a,9,10,10a-octahydrophenanthrene-2,3,7-triol 645398-32-9P , (2R,3S,4aR,10aR)-4a-Ethyl-2-(pyridin-2-yl)-1,2,3,4,4a,9,10,10a-octahydrophenanthrene-2,3,7-triol 645398-33-0P 645398-34-1P 645398-36-3P 645398-37-4P


L12 ANSWER 4 OF 15 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 645398-40-9P 645398-42-1P 645398-43-2P
 (2R,3R,4R,10aR)-2-Benzyl-4a-ethyl-3-methyl-1,2,3,4,4a,9,10,10a-octahydrophenanthrene-2,3,7-triol 645398-44-3P
 645398-46-5P 645398-47-6P 645398-48-7P
 645398-49-8P 645398-50-1P, (2R,3R,4R,10aR)-4a-Ethyl-3-methyl-2-prop-1-ynyl-1,2,3,4,4a,9,10,10a-octahydrophenanthrene-2,3,7-triol 645398-51-2P 645398-53-4P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (glucocorticoid receptor modulator; prepn. of octahydrophenanthrenols as glucocorticoid receptor modulators for treatment of inflammatory conditions)
 RN 645397-13-3 HCAPLUS
 CN 2,3,7-Phenanthrenetriol, 4a-ethyl-1,2,3,4,4a,9,10,10a-octahydro-2-(1-propynyl)-, (2R,3S,4aR,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 645397-14-4 HCAPLUS
 CN 2,3-Phenanthrenediol, 4a-ethyl-1,2,3,4,4a,9,10,10a-octahydro-7-[(2-methyl-3-pyridinyl)methoxy]-2-(1-propynyl)-, (2R,3S,4aR,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 645397-15-5 HCAPLUS
 CN 2,3-Phenanthrenediol, 4a-ethyl-1,2,3,4,4a,9,10,10a-octahydro-2-(1-propynyl)-7-(2-pyridinylmethoxy)-, (2R,3S,4aR,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L12 ANSWER 4 OF 15 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 CN 2,3-Phenanthrenediol, 4a-ethyl-1,2,3,4,4a,9,10,10a-octahydro-2-(1-propynyl)-7-(3-pyridinylmethoxy)-, (2R,3S,4aR,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 645397-19-9 HCAPLUS
 CN 2,3-Phenanthrenediol, 4a-ethyl-1,2,3,4,4a,9,10,10a-octahydro-7-[(6-methyl-3-pyridinyl)methoxy]-2-(1-propynyl)-, (2R,3S,4aR,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 645397-20-2 HCAPLUS
 CN 2,3-Phenanthrenediol, 7-[(5-[(diethylamino)methyl]-1,2,4-oxadiazol-3-yl)methoxy]-4a-ethyl-1,2,3,4,4a,9,10,10a-octahydro-2-(1-propynyl)-, (2R,3S,4aR,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 645397-23-5 HCAPLUS

L12 ANSWER 4 OF 15 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 645397-16-6 HCAPLUS
 CN 2,3-Phenanthrenetriol, 4a-ethyl-1,2,3,4,4a,9,10,10a-octahydro-2-(1-propynyl)-7-(4-pyridinylmethoxy)-, (2R,3S,4aR,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 645397-17-7 HCAPLUS
 CN 2,3-Phenanthrenetriol, 7-((2,4-dimethyl-3-pyridinyl)methoxy)-4a-ethyl-1,2,3,4,4a,9,10,10a-octahydro-2-(1-propynyl)-, (2R,3S,4aR,10aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 645397-18-8 HCAPLUS


L12 ANSWER 4 OF 15 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 CN Carbamic acid, [2-(dimethylamino)ethyl]methyl-, (4b,6S,7R,8aR)-4b-ethyl-4b,5,6,7,8,8a,9,10-octahydro-7-dihydroxy-7-(1-propynyl)-2-phenanthrenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 645397-24-6 HCAPLUS
 CN 2,3,7-Phenanthrenetriol, 2-butyl-4a-ethyl-1,2,3,4,4a,9,10,10a-octahydro-, (2S,3S,4aR,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 645397-25-7 HCAPLUS
 CN 2,3,7-Phenanthrenetriol, 2-butyl-4a-ethyl-1,2,3,4,4a,9,10,10a-octahydro-, (2R,3S,4aR,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 645397-26-8 HCAPLUS
 CN 2,3,7-Phenanthrenetriol, 2-(3-chloro-5-fluorophenyl)-4a-ethyl-1,2,3,4,4a,9,10,10a-octahydro-, (2R,3S,4aR,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 645397-27-9 HCAPLUS
 CN 2,3-Phenanthrenediol, 2-(3-chloro-5-fluorophenyl)-4a-ethyl-1,2,3,4,4a,9,10,10a-octahydro-7-[(2-methyl-3-pyridinyl)methoxy]-, (2R,3S,4aR,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 645397-28-0 HCAPLUS
 CN 2,3-Phenanthrenediol, 4a-ethyl-1,2,3,4,4a,9,10,10a-octahydro-2-(5-methyl-2-thiazolyl)-, (2R,3S,4aR,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 645397-29-1 HCAPLUS
 CN 2,3,7-Phenanthrenetriol, 2-(4,5-dimethyl-2-thiazolyl)-4a-ethyl-1,2,3,4,4a,9,10,10a-octahydro-, (2R,3S,4aR,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 645397-30-4 HCAPLUS
 CN 2,3,7-Phenanthrenetriol, 4a-ethyl-1,2,3,4,4a,9,10,10a-octahydro-2-(trifluoromethyl)-, (2R,3S,4aR,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 645397-32-6 HCAPLUS
 CN 2,3-Phenanthrenediol, 4a-ethyl-1,2,3,4,4a,9,10,10a-octahydro-2-phenyl-7-(4-pyridinylmethoxy)-, (2R,3S,4aR,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 645397-33-7 HCAPLUS
 CN 2,3-Phenanthrenediol, 4a-ethyl-1,2,3,4,4a,9,10,10a-octahydro-2-phenyl-7-(3-pyridinylmethoxy)-, (2R,3S,4aR,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 645397-34-8 HCAPLUS
 CN 2,3-Phenanthrenediol, 4a-ethyl-1,2,3,4,4a,9,10,10a-octahydro-7-[(2-methyl-3-pyridinyl)methoxy]-2-phenyl-, (2R,3S,4aR,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 645397-35-9 HCAPLUS
 CN 2,3,7-Phenanthrenetriol, 1,2,3,4,4a,9,10,10a-octahydro-2-phenyl-4a-(2-propenyl)-, (2R,3S,4aR,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 645397-36-0 HCAPLUS
 CN 2,3,7-Phenanthrenetriol, 4a-ethyl-1,2,3,4,4a,9,10,10a-octahydro-2-(phenylmethyl)-, (2R,3S,4aR,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 645397-37-1 HCAPLUS
 CN 2,3-Phenanthrenediol, 4a-ethyl-1,2,3,4,4a,9,10,10a-octahydro-2-(phenylmethyl)-, (2R,3S,4aR,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 645397-38-2 HCAPLUS
 CN 2,3,7-Phenanthrenetriol, 1,2,3,4,4a,9,10,10a-octahydro-2-(phenylmethyl)-4a-(2-propenyl)-, (2R,3S,4aR,10aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



L12 ANSWER 4 OF 15 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)


RN 645397-39-3 HCAPLUS
 CN 2,3,7-Phenanthrenetriol, 1,2,3,4,4a,9,10,10a-octahydro-2-(phenylmethyl)-4a-(2-propenyl)-, (2R,3S,4aR,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 645397-40-6 HCAPLUS
 CN 2,3,7-Phenanthrenetriol, 1,2,3,4,4a,9,10,10a-octahydro-2,4a-di-2-propenyl-, (2R,3S,4aR,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 645397-41-7 HCAPLUS
 CN 2,3,7-Phenanthrenetriol, 1,2,3,4,4a,9,10,10a-octahydro-2,4a-di-2-propenyl-, (2R,3S,4aR,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 645397-42-8 HCAPLUS
 CN 2,3,7-Phenanthrenetriol, 4a-ethyl-1,2,3,4,4a,9,10,10a-octahydro-2-(3-pyridinyl)-, (2R,3S,4aR,10aR)- (9CI) (CA INDEX NAME)

L12 ANSWER 4 OF 15 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 Absolute stereochemistry.


RN 645397-46-2 HCAPLUS
 CN 2,3-Phenanthrenediol, 4a-ethyl-2-(4-fluorophenyl)-1,2,3,4,4a,9,10,10a-octahydro-7-(2-methyl-3-pyridinyl)methoxy-, (2R,3S,4aR,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 645397-50-8 HCAPLUS
 CN 2,3-Phenanthrenediol, 1,2,3,4,4a,9,10,10a-octahydro-2-phenyl-4a-(phenylmethyl)-7-(4-pyridinylmethoxy)-, (2R,3S,4aR,10aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



L12 ANSWER 4 OF 15 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)


RN 645397-51-9 HCAPLUS
 CN 2,3-Phenanthrenediol, 1,2,3,4,4a,9,10,10a-octahydro-7-((2-methyl-3-pyridinyl)methoxy)-2-phenyl-4a-(phenylmethyl)-, (2R,3S,4aR,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 645397-53-1 HCAPLUS
 CN 2-Phenanthrenecarboxamide, 4b-ethyl-4b,5,6,7,8,8a,9,10-octahydro-6,7-dihydroxy-N-((2-methyl-3-pyridinyl)methyl)-7-(1-propynyl)-, (4R,6S,7R,8aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 645397-56-4 HCAPLUS
 CN 2,3,7-Phenanthrenetriol, 2-(2,6-dimethoxyphenyl)-4a-ethyl-1,2,3,4,4a,9,10,10a-octahydro-, (2R,3S,4aR,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 645397-57-5 HCAPLUS

L12 ANSWER 4 OF 15 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 CN 2,3,7-Phenanthrenetriol, 1,2,3,4,4a,9,10,10a-octahydro-2-(2-methoxyphenyl)-, (2R,3S,4aR,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 645397-58-6 HCAPLUS
 CN 2,3,7,9-Phenanthrenetetrol, 4a-ethyl-1,2,3,4,4a,9,10,10a-octahydro-2-(2-methoxyphenyl)-, (2R,3S,4aR,9R,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


RN 645397-60-0 HCAPLUS
 CN 9(1H)-Phenanthrenone, 4a-ethyl-2,3,4,4a,10,10a-hexahydro-2,3,7-trihydroxy-2-phenyl-, (2R,3S,4aR,10aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 645397-61-1 HCAPLUS
 CN 2,7-Phenanthrenediol, 3-amino-4a-ethyl-1,2,3,4,4a,9,10,10a-octahydro-2-phenyl-, (2R,3S,4aR,10aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

Page 4821/03/2006




RN 645397-63-3 HCAPLUS
CN 2,3,7-Phenanthrenetriol, 4a-ethyl-1,2,3,4,4a,9,10,10a-octahydro-3-methyl-2-phenyl-, (2R,3S,4aR,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 645397-65-5 HCAPLUS
CN 2,3,7-Phenanthrenetriol, 4a-ethyl-1,2,3,4,4a,10a-hexahydro-3,9-dimethyl-2-phenyl-, (2R,3S,4aR,10aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 645397-66-6 HCAPLUS
CN 2,3,7-Phenanthrenetriol, 4a-ethyl-1,2,3,4,4a,10a-hexahydro-3,9-dimethyl-2-phenyl-, (2R,3R,4aR,10aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 645397-67-7 HCAPLUS
CN 2,3,7-Phenanthrenetriol, 4a-ethyl-1,2,3,4,4a,10,10a-hexahydro-3,7-trihydroxy-3-methyl-2-phenyl-, (2R,3S,4aR,10aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 645397-68-8 HCAPLUS
CN 2,3,7-Phenanthrenetriol, 3,4a-diethyl-1,2,3,4,4a,9,10,10a-octahydro-2-phenyl-, (2R,3R,4aR,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 645397-69-9 HCAPLUS
CN 2,3,7-Phenanthrenetriol, 4a-ethyl-1,2,3,4,4a,9,10,10a-octahydro-3-(1-methylethyl)-2-phenyl-, (2R,3S,4aR,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 645397-70-2 HCAPLUS
CN 2,3,7-Phenanthrenetriol, 3-cyclopropyl-4a-ethyl-1,2,3,4,4a,9,10,10a-octahydro-2-phenyl-, (2R,3S,4aR,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 645397-71-3 HCAPLUS
CN 2,3,7-Phenanthrenetriol, 4a-ethyl-1,2,3,4,4a,9,10,10a-octahydro-2-phenyl-, (2R,3R,4aR,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 645397-72-4 HCAPLUS
CN 2,3,7-Phenanthrenetriol, 3-ethenyl-4a-ethyl-1,2,3,4,4a,9,10,10a-octahydro-2-phenyl-, (2R,3S,4aR,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 645397-73-5 HCAPLUS
CN 2,3,7-Phenanthrenetriol, 4a-ethyl-3-ethynyl-1,2,3,4,4a,9,10,10a-octahydro-2-phenyl-, (2R,3S,4aR,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 645397-74-6 HCAPLUS
CN 2,3,7-Phenanthrenetriol, 2-cyclopropyl-4a-ethyl-1,2,3,4,4a,9,10,10a-octahydro-3-methyl-, (2R,3R,4aR,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 645397-75-7 HCAPLUS
CN 2,3,7-Phenanthrenetriol, 2-cyclopropyl-4a-ethyl-1,2,3,4,4a,9,10,10a-octahydro-3-phenyl-, (2R,3S,4aR,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 645397-76-8 HCPLUS
 CN 2,3-Phenanthrenediol, 2-(2,6-difluorophenyl)-4a-ethyl-1,2,3,4,4a,9,10,10a-octahydro-7-[(2-methyl-3-pyridinyl)methoxy]-, (2R,3S,4aR,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 645397-77-9 HCPLUS
 CN 2,3-Phenanthrenediol, 4a-ethyl-1,2,3,4,4a,9,10,10a-octahydro-3-methyl-7-[(2-methyl-3-pyridinyl)methoxy]-2-phenyl-, (2R,3R,4aR,10aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 645397-78-0 HCPLUS


L12 ANSWER 4 OF 15 HCPLUS COPYRIGHT 2006 ACS on STN (Continued)
 CN 2,3-Phenanthrenediol, 4a-ethyl-1,2,3,4,4a,9,10,10a-octahydro-7-methoxy-3-methyl-2-phenyl-, (2R,3R,4aR,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 645397-79-1 HCPLUS
 CN 2,3-Phenanthrenediol, 4a-ethyl-1,2,3,4,4a,9,10,10a-octahydro-7-(2-hydroxyethoxy)-3-methyl-2-phenyl-, (2R,3R,4aR,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 645397-80-4 HCPLUS
 CN 2,3-Phenanthrenediol, 4a-ethyl-1,2,3,4,4a,9,10,10a-octahydro-7-(3-hydroxypropoxy)-3-methyl-2-phenyl-, (2R,3R,4aR,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 645397-81-5 HCPLUS
 CN 2,3-Phenanthrenediol, 4a-ethyl-1,2,3,4,4a,9,10,10a-octahydro-7-(4-hydroxybutoxy)-3-methyl-2-phenyl-, (2R,3R,4aR,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 645397-88-2 HCPLUS
 CN Acetamide, 2-[(4bR,6R,7R,8aR)-4b-ethyl-4b,5,6,7,8,8a,9,10-octahydro-6,7-dihydroxy-6-methyl-7-phenyl-2-phenanthrenyloxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 645397-90-6 HCPLUS
 CN Butanoic acid, 4-[(4bR,6R,7R,8aR)-4b-ethyl-4b,5,6,7,8,8a,9,10-octahydro-6,7-dihydroxy-6-methyl-7-phenyl-2-phenanthrenyloxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 645397-91-7 HCPLUS
 CN Pentanoic acid, 5-[(4bR,6R,7R,8aR)-4b-ethyl-4b,5,6,7,8,8a,9,10-octahydro-6,7-dihydroxy-6-methyl-7-phenyl-2-phenanthrenyloxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 645397-92-8 HCPLUS
 CN 2,3-Phenanthrenediol, 4a-ethyl-1,2,3,4,4a,9,10,10a-octahydro-7-(2-hydroxy-2-methylpropoxy)-3-methyl-2-phenyl-, (2R,3R,4aR,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 645397-93-9 HCPLUS
 CN 2,3-Phenanthrenediol, 4a-ethyl-1,2,3,4,4a,9,10,10a-octahydro-3-methyl-2-phenyl-7-(1H-tetrazol-5-ylmethoxy)-, (2R,3R,4aR,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 645397-94-0 HCPLUS
 CN 2,3-Phenanthrenediol, 4a-ethyl-1,2,3,4,4a,9,10,10a-octahydro-3-methyl-2-phenyl-7-(3-(1H-tetrazol-5-yl)propoxy)-, (2R,3R,4aR,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 645397-95-1 HCPLUS
 CN 2,3,7-Phenanthrenediol, 4a-ethyl-1,2,3,4,4a,9,10,10a-octahydro-3-methyl-2-phenyl-7-[4-(1H-tetrazol-5-yl)butoxy]-, (2R,3R,4aR,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 645397-96-2 HCPLUS
 CN Acetamide, N-(3-cyanopropyl)-2-[(4bR,6R,7R,8aR)-4b-ethyl-4b,5,6,7,8,8a,9,10-octahydro-6,7-dihydroxy-6-methyl-2-phenanthrenyloxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 645397-97-3 HCPLUS
 CN 2,3,7-Phenanthrenetriol, 2-ethenyl-4a-ethyl-1,2,3,4,4a,9,10,10a-octahydro-




RN 645398-01-2 HCPLUS
 CN 2,3,7-Phenanthrenetriol, 4a-ethyl-1,2,3,4,4a,9,10,10a-octahydro-3-methyl-2-(1E)-1-propenyl-, (2R,3R,4aR,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.



RN 645398-02-3 HCPLUS
 CN 2,3,7-Phenanthrenetriol, 2,4a-diethyl-1,2,3,4,4a,9,10,10a-octahydro-3-methyl-, (2S,3R,4aR,10aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 645398-03-4 HCPLUS
 CN 2,3,7-Phenanthrenetriol, 4a-ethyl-1,2,3,4,4a,9,10,10a-octahydro-3-methyl-2-propyl-, (2S,3R,4aR,10aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

Absolute stereochemistry.




RN 645397-98-4 HCPLUS
 CN 2,3,7-Phenanthrenetriol, 4a-ethyl-1,2,3,4,4a,9,10,10a-octahydro-3-methyl-2-(1-methylethyl)-, (2R,3R,4aR,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 645397-99-5 HCPLUS
 CN 2,3,7-Phenanthrenetriol, 4a-ethyl-1,2,3,4,4a,9,10,10a-octahydro-3-methyl-2-(2-propynyl)-, (2R,3R,4aR,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 645398-00-1 HCPLUS
 CN 2,3,7-Phenanthrenetriol, 4a-ethyl-1,2,3,4,4a,9,10,10a-octahydro-3-methyl-2-(4-methylphenyl)-, (2R,3R,4aR,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 645398-04-5 HCPLUS
 CN 2,3,7-Phenanthrenetriol, 2-butyl-4a-ethyl-1,2,3,4,4a,9,10,10a-octahydro-3-methyl-, (2S,3R,4aR,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 645398-05-6 HCPLUS
 CN 2,3,7-Phenanthrenetriol, 4a-ethyl-1,2,3,4,4a,9,10,10a-octahydro-3-methyl-2-(2-propenyl)-, (2S,3R,4aR,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 645398-06-7 HCPLUS
 CN 2,3-Phenanthrenediol, 7-[[5-(dimethylamino)methyl]-1,2,4-oxadiazol-3-yl]methoxy-4a-ethyl-1,2,3,4,4a,9,10,10a-octahydro-3-methyl-2-phenyl-, (2R,3R,4aR,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 645398-07-8 HCPLUS
 CN 2,3-Phenanthrenediol, 4a-ethyl-1,2,3,4,4a,9,10,10a-octahydro-3-methyl-7-[(5-[2-(4-morpholinyl)ethyl]-1,2,4-oxadiazol-3-yl)methoxy]-2-phenyl-, (2R,3R,4aR,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 645398-08-9 HCPLUS
 CN 2,3-Phenanthrenediol, 7-[(5-[2-(dimethylamino)ethyl]-1,2,4-oxadiazol-3-yl)methoxy]-4a-ethyl-1,2,3,4,4a,9,10,10a-octahydro-3-methyl-2-phenyl-, (2R,3R,4aR,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 645398-09-0 HCPLUS
 CN 2,3-Phenanthrenediol, 4a-ethyl-1,2,3,4,4a,9,10,10a-octahydro-3-methyl-2-phenyl-7-[(5-[2-(1-piperidinyl)ethyl]-1,2,4-oxadiazol-3-yl)methoxy]-, (2R,3R,4aR,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 645398-13-6 HCPLUS
 CN Piperazine, 1-[(4bR,6R,7R,8aR)-4b-ethyl-4b,5,6,7,8,8a,9,10-octahydro-6,7-dihydroxy-6-methyl-7-phenyl-2-phenanthrenyl]oxy]acetyl]-4-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 645398-14-7 HCPLUS
 CN Acetanilide, 2-[(4bR,6R,7R,8aR)-4b-ethyl-4b,5,6,7,8,8a,9,10-octahydro-6,7-dihydroxy-6-methyl-7-phenyl-2-phenanthrenyl]oxy]-N-(4-pyridinylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 645398-15-8 HCPLUS
 CN 2,3-Phenanthrenediol, 4a-ethyl-1,2,3,4,4a,9,10,10a-octahydro-3-methyl-7-(2-(4-morpholinyl)ethoxy)-2-phenyl-, (2R,3R,4aR,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 645398-10-3 HCPLUS
 CN Acetamide, N-[(3-[(4bR,6R,7R,8aR)-4b-ethyl-4b,5,6,7,8,8a,9,10-octahydro-6,7-dihydroxy-6-methyl-7-phenyl-2-phenanthrenyl]oxy)methyl]-1,2,4-oxadiazol-5-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 645398-11-4 HCPLUS
 CN 2,3-Phenanthrenediol, 4a-ethyl-1,2,3,4,4a,9,10,10a-octahydro-3-methyl-7-[(5-[(1-methyl-1H-pyrrol-2-yl)methyl]-1,2,4-oxadiazol-3-yl)methoxy]-2-phenyl-, (2R,3R,4aR,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 645398-12-5 HCPLUS
 CN Morpholine, 4-[(4bR,6R,7R,8aR)-4b-ethyl-4b,5,6,7,8,8a,9,10-octahydro-6,7-




RN 645398-16-9 HCPLUS
 CN 2,3-Phenanthrenediol, 4a-ethyl-1,2,3,4,4a,9,10,10a-octahydro-3-methyl-2-phenyl-7-[2-(1-piperidinyl)ethoxy]-, (2R,3R,4aR,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 645398-17-0 HCPLUS
 CN 9(1H)-Phenanthrenone, 4a-ethyl-2,3,4,4a,10,10a-hexahydro-2,3-dihydroxy-3-methyl-7-[(2-methyl-3-pyridinyl)methoxy]-2-phenyl-, (2R,3R,4aR,10aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 645398-18-1 HCPLUS
 CN 2,3-Phenanthrenetriol, 4a-ethyl-1,2,3,4,4a,9,10,10a-octahydro-3-methyl-2-(2-pyridinyl)-, (2R,3R,4aR,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 645398-19-2 HCAPLUS
CN 2,3,7-Phenanthrenetriol, 4a-ethyl-1,2,3,4,4a,9,10,10a-octahydro-3-methyl-2-(3-pyridinyl)-, (2R,3R,4aR,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 645398-21-6 HCAPLUS
CN 2,3,7-Phenanthrenetriol, 4a-ethyl-1,2,3,4,4a,9,10,10a-octahydro-3-methyl-2-(4-pyridinyl)-, (2R,3R,4aR,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 645398-23-8 HCAPLUS
CN 2,3-Phenanthrenediol, 4a-ethyl-1,2,3,4,4a,9,10,10a-octahydro-3-methyl-7-[(2-methyl-3-pyridinyl)methoxy]-2-(2-pyridinyl)-, (2R,3R,4aR,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 645398-27-2 HCAPLUS
CN Acetamide, N-[[3-[(4bR,6R,7R,8aR)-4b-ethyl-4b,5,6,7,8,8a,9,10-octahydro-6,7-dihydroxy-6-methyl-7-(2-pyridinyl)-2-phenanthrenyl]oxy]methyl]-1,2,4-oxadiazol-3-yl]methoxy]-4a-ethyl-1,2,3,4,4a,9,10,10a-octahydro-3-methyl-2-(2-pyridinyl)-, (2R,3R,4aR,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 645398-28-3 HCAPLUS
CN 2,3-Phenanthrenediol, 7-[(5-[2-(dimethylamino)ethyl]-1,2,4-oxadiazol-3-yl)methoxy]-4a-ethyl-1,2,3,4,4a,9,10,10a-octahydro-3-methyl-2-(2-pyridinyl)-, (2R,3R,4aR,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 645398-30-7 HCAPLUS
CN Acetamide, 2-[(4bR,6R,7R,8aS)-4b-ethyl-4b,5,6,7,8,8a,9,10-octahydro-6,7-



RN 645398-24-9 HCAPLUS
CN Acetamide, 2-[(4bR,6R,7R,8aR)-4b-ethyl-4b,5,6,7,8,8a,9,10-octahydro-6,7-dihydroxy-6-methyl-7-(2-pyridinyl)-2-phenanthrenyl]oxy]-4a-ethyl-1,2,3,4,4a,9,10,10a-octahydro-3-methyl-2-(2-pyridinyl)-, (2R,3R,4aR,10aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 645398-26-1 HCAPLUS
CN 2,3-Phenanthrenediol, 7-[(5-[2-(1-azetidinyl)ethyl]-1,2,4-oxadiazol-3-yl)methoxy]-4a-ethyl-1,2,3,4,4a,9,10,10a-octahydro-3-methyl-2-(2-pyridinyl)-, (2R,3R,4aR,10aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

Absolute stereochemistry.




RN 645398-31-8 HCAPLUS
CN 2,3,7-Phenanthrenetriol, 4a-ethyl-1,2,3,4,4a,9,10,10a-octahydro-2-(2-pyridinyl)-, (2R,3S,4aR,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 645398-32-9 HCAPLUS
CN 2,3,7-Phenanthrenetriol, 4a-ethyl-1,2,3,4,4a,9,10,10a-octahydro-2-(2-pyridinyl)-, (2R,3R,4aR,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 645398-33-0 HCAPLUS
CN 2,3,7-Phenanthrenetriol, 4a-ethyl-1,2,3,4,4a,9,10,10a-octahydro-3-methyl-2-(2-thiazolyl)-, (2R,3R,4aR,10aR)- (9CI) (CA INDEX NAME)




RN 645398-34-1 HCPLUS
CN 2,3,7-Phenanthrenetriol, 2-(4,5-dimethyl-2-thiazolyl)-4a-ethyl-1,2,3,4,4a,9,10,10a-octahydro-3-methyl-, (2R,3R,4aR,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 645398-36-3 HCPLUS
CN 2,3,7-Phenanthrenetriol, 4a-ethyl-1,2,3,4,4a,9,10,10a-octahydro-3-methyl-2-(4-methyl-2-thiazolyl)-, (2R,3R,4aR,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 645398-37-4 HCPLUS
CN 2,3,7-Phenanthrenetriol, 4a-ethyl-1,2,3,4,4a,9,10,10a-octahydro-3-methyl-2-(5-methyl-2-thiazolyl)-, (2R,3R,4aR,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 645398-44-3 HCPLUS
CN 2,3,7-Phenanthrenetriol, 1,2,3,4,4a,9,10,10a-octahydro-2-phenyl-4a-propyl-, (2R,3S,4aR,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 645398-46-5 HCPLUS
CN 2,3,7-Phenanthrenetriol, 4a-ethyl-1,2,3,4,4a,9,10,10a-octahydro-3-methyl-2-(2-thiazolyl)-, (2R,3S,4aR,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 645398-47-6 HCPLUS
CN 2,3,7-Phenanthrenetriol, 4a-ethyl-1,2,3,4,4a,9,10,10a-octahydro-3-methyl-2-(4-methyl-2-thiazolyl)-, (2R,3S,4aR,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 645398-40-9 HCPLUS
CN 2,3,7-Phenanthrenetriol, 1-((4bR,6S,7R,8aR)-4b-ethyl-4b,5,6,7,8,8a,9,10-octahydro-6,7-dihydroxy-6-methyl-7-phenyl-2-phenanthrenyl)-, (2R,3R,4aR,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 645398-42-1 HCPLUS
CN 2,3,7-Phenanthrenetriol, 4a-ethyl-1,2,3,4,4a,9,10,10a-octahydro-7-(1-hydroxy-1-methyl-ethyl)-3-methyl-2-phenyl-, (2R,3R,4aR,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 645398-43-2 HCPLUS
CN 2,3,7-Phenanthrenetriol, 4a-ethyl-1,2,3,4,4a,9,10,10a-octahydro-3-methyl-2-(phenylmethyl)-, (2R,3R,4aR,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 645398-48-7 HCPLUS
CN 2,3,7-Phenanthrenetriol, 1-((4bR,6S,7R,8aR)-4b-ethyl-4b,5,6,7,8,8a,9,10-octahydro-7-(4-hydroxy-4-methylpentyl)oxy)-3-methyl-2-phenyl-, (2R,3R,4aR,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 645398-49-8 HCPLUS
CN 2,3,7-Phenanthrenetriol, 4a-ethyl-1,2,3,4,4a,9,10,10a-octahydro-7-((5-hydroxy-5-methylhexyl)oxy)-3-methyl-2-phenyl-, (2R,3R,4aR,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 645398-50-1 HCPLUS
CN 2,3,7-Phenanthrenetriol, 4a-ethyl-1,2,3,4,4a,9,10,10a-octahydro-3-methyl-2-(1-propynyl)-, (2R,3R,4aR,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 645398-51-2 HCAPLUS
 CN 2,3,7-Phenanthrenetriol, 4a-ethyl-1,2,3,4,4a,9,10,10a-octahydro-3-methyl-2-(1-propenyl)-, (2R,3R,4aR,10aR)- (9CI). (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry unknown.



RN 645398-53-4 HCAPLUS
 CN 2,3,7-Phenanthrenetriol, 4a-ethyl-1,2,3,4,4a,9,10,10a-octahydro-2,3-dimethyl-, (2S,3R,4aR,10aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



IT 645397-03-1P 645397-44-0P 645397-54-2P, (6S,7R,4BR,8aR)-4b-ethyl-6,7-dihydroxy-7-prop-1-ynyl-4b,5,6,7,8,8a,9,10-octahydrophenanthrene-2-carboxylic acid
 RL: RCT (Reactant); SPPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (intermediate; preparation of octahydrophenanthrenols as glucocorticoid receptor modulators for treatment of inflammatory conditions)


RN 645397-03-1 HCAPLUS
 CN 2,3-Phenanthrenediol, 7-[3-[(1,1-dimethylethyl)dimethylsilyloxy]propoxy]-

Absolute stereochemistry.




RN 645397-44-0 HCAPLUS
 CN 2,3-Phenanthrenediol, 7-[(1,1-dimethylethyl)dimethylsilyloxy]-4a-ethyl-1,2,3,4,4a,9,10,10a-octahydro-3-(3-pyridinyl)-, (2R,3S,4aR,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 645397-54-2 HCAPLUS
 CN 2-Phenanthrenecarboxylic acid, 4b-ethyl-4b,5,6,7,8,8a,9,10-octahydro-6,7-dihydroxy-7-(1-propynyl)-, (4bR,6S,7R,8aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

ED Entered STN: 18 Nov 2003

AB An unusual 29-nor-3,4-seco-friedelan-4(23),20(30)-dien-3-oic acid and a new 5-hydroxy-6,9-epoxyguaiane have been isolated along with other rare terpenes and lignans from *Phyllanthus oxyphyllus* roots. Their structures were elucidated from spectroscopic data. The radical scavenging properties of some of these compds. were evaluated. seco-Isoalariciresinol showed strong antioxidant activity (IC50 0.017±0.001 mM).

ACCESSION NUMBER: 2003:900400 HCAPLUS

DOCUMENT NUMBER: 140:160476

TITLE: A novel 29-nor-3,4-seco-friedelane triterpene and a new guaiane sesquiterpene from the roots of *Phyllanthus oxyphyllus*

AUTHOR(S): Sutthivaiyakit, Somote; Nakorn, Narissara Na; Kraus, Wolfgang; Sutthivaiyakit, Pakawadee

CORPORATE SOURCE: Faculty of Science, Department of Chemistry, Ramkhamhaeng University, Bangkok, 10240, Thailand

SOURCE: Tetrahedron (2003), 59(50), 9991-9995

CODEN: TETRAB; ISSN: 0040-4020

PUBLISHER: Elsevier Science B.V.

DOCUMENT TYPE: Journal


LANGUAGE: English

IT 24465-21-2, Cleistanthol

RL: BSU (Biological study, unclassified); NPO (Natural product occurrence); BIOL (Biological study); OCCU (Occurrence) (triterpene and a guaiane sesquiterpene from the roots of *Phyllanthus oxyphyllus*)

RN 24465-21-2 HCAPLUS
 CN 2,3,6-Phenanthrenetriol, 8-ethenyl-1,2,3,4,4a,9,10,10a-octahydro-1,1,4a,7-tetramethyl-, (2S,3R,4aR,10aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 21 THERE ARE 21 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

ED Entered STN: 03 Oct 2003

AB Integracides, 4,4-dimethylergostane triterpenoids, are inhibitors of HIV-1 integrase, a critical enzyme in replication of HIV-1. The chemical and structure-activity relation of integracide B and related natural products are described. A charged group, e.g., a sulfate, carboxyl, or amino, is required for the HIV-1 integrase activity. These compds. showed HIV-1 integrase activity with IC50 values in the range 4.8-15 μ M and exhibited antiviral activity in a viral spread assay, but with only a small or no therapeutic window.

ACCESSION NUMBER: 2003:772365 HCAPLUS

DOCUMENT NUMBER: 140:232

TITLE: Chemistry and Structure-Activity Relationship of HIV-1 Integrase Inhibitor Integracide B and Related Natural Products

AUTHOR(S): Singh, Sheo B.; Ondeyka, John G.; Schleif, William A.; Felock, Peter; Hazuda, Dari J.

CORPORATE SOURCE: Merck Research Laboratories, Rahway, NJ, 07065, USA

SOURCE: Journal of Natural Products (2003), 66(10), 1338-1344

CODEN: JNPRDF; ISSN: 0163-3864

PUBLISHER: American Chemical Society

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 140:232

IT 304641-66-5 304641-67-6


RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(chemical and structure-activity relationship of HIV-1 integrase inhibitor integracide B and related natural products)

RN 304641-66-5 HCAPLUS


CN 18-Norergosta-8,11,13,24(28)-tetraene-2,3-diol, 15-methoxy-4,4,12-trimethyl-, (2a,3b,5a,15b)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 304641-67-6 HCAPLUS
 CN 18-Norergosta-8,11,13,24(28)-tetraene-2,3-diol, 15-methoxy-4,4,12-trimethyl-, (2a,3b,5a,15b)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 27 THERE ARE 27 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

ED Entered STN: 30 Mar 2003

AB The conversion of 2a,3a-dioxy-substituted phyllocladane derivatives, into the corresponding 3-ketone proceeds in an unexpected manner: Depending on the reaction conditions, the corresponding 3B-hydroxy-substituted compound is formed almost quant., or the desired ketone can be isolated directly. The reaction mechanism is now disclosed to be a stereospecific C(3) \rightarrow C(2)-hydride shift by investigating the reactions of the synthesized (t)-trans-decalin-type (trans-1,2,3,4,4a,9,10,10a-octahydro-1,1,4a-trimethylphenanthrenes) model compds. and of their D-labeled isomers. The latter afforded the corresponding 3B-hydroxy (2R)-derivs. as well as the (2B-D)-3-ketones, thus evidencing a suprafacial (C3) \rightarrow C(2)-deuteride shift. This reaction mechanism seems to be a general feature of such 3a,4a-dioxy-substituted 1,5,5-trimethylbicyclo[4.4.0]decan congeners.

ACCESSION NUMBER: 2003:242961 HCPLUS

DOCUMENT NUMBER: 139:36643

TITLE: An unexpected (3 \rightarrow 2)-hydride shift in phyllocladane (= 13B-kaurene) diterpenoids and in related trimethyl-substituted bi- and tricyclic compounds

AUTHOR(S): Muller, Ralph; Ruedi, Peter

CORPORATE SOURCE: Organisch-chemisches Institut der Universitat Zurich, Zurich, CH-8057, Switz.

SOURCE: Helvetica Chimica Acta (2003), 86(2), 439-456

CODEN: HCACAV; ISSN: 0018-019X

PUBLISHER: Verlag Helvetica Chimica Acta

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 139:36643

IT 544476-60-0P 544476-85-9P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

((3-2)-hydride shift in phyllocladane diterpenoids and in related tri-Me-substituted bi- and tricyclic compds.)

RN 544476-60-0 HCPLUS

CN 2,3-Phenanthrendiol, 1,2,3,4,4a,9,10,10a-octahydro-1,1,4a-trimethyl-, (2R,3S,4aR,10aS)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 544476-85-9 HCPLUS

CN 2,3-Phenanthrendiol, 1,2,3,4,4a,9,10,10a-octahydro-2-d-1,1,4a-trimethyl-, (2R,3S,4aR,10aS)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



REFERENCE COUNT: 30 THERE ARE 30 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

ED Entered STN: 03 Jun 2001

GI



AB Exts. of the stems of Jatropha divaricata have yielded the two new diterpenes ent-3B,14a-hydroxypimarane-7,9(11),15-triene-12-one (I) and the rearranged pinamarane ent-15(13-8)abeo-8B(ethyl)pimarane (II), which appear to be a new skeletal type. The rare cleistanthane diterpenes spruceanol and cleistanthol were also obtained.

ACCESSION NUMBER: 2001:397285 HCPLUS

DOCUMENT NUMBER: 135:149913

TITLE: New diterpenes from Jatropha divaricata

AUTHOR(S): Denton, Richard W.; Harding, Wayne W.; Anderson, Chadwick I.; Jacobs, Helen; McLean, Stewart; Reynolds, William F.

CORPORATE SOURCE: Department of Chemistry, University of the West Indies, Mona Kingston, Jamaica

SOURCE: Journal of Natural Products (2001), 64(6), 829-831

CODEN: JNPDFD; ISSN: 0163-3864

PUBLISHER: American Chemical Society

DOCUMENT TYPE: Journal

LANGUAGE: English

IT 24465-21-2, Cleistanthol


RL: BOC (Biological occurrence); BSU (Biological study, unclassified); BIOL (Biological study); OCCU (Occurrence)

(diterpenes from Jatropha divaricata)

RN 24465-21-2 HCPLUS

CN 2,3,6-Phenanthrenetriol, 8-ethenyl-1,2,3,4,4a,9,10,10a-octahydro-1,1a,7-tetramethyl-, (2S,3R,4aR,10aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L12 ANSWER 8 OF 15 HCPLUS COPYRIGHT 2006 ACS on STN (Continued)
 REFERENCE COUNT: 15 THERE ARE 15 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 9 OF 15 HCPLUS COPYRIGHT 2006 ACS on STN
 ED Entered STN: 06 Sep 2000
 AB Tetracyclic triterpenoids containing the 12-acetyl-A8,14-diene-11-ol moiety undergo a series of acid-catalyzed rearrangements. The rearrangement products have been characterized, plausible mechanisms for the rearrangement have been elucidated and conditions have been developed to give high yields of the rearrangement products. A new and general PTSA-H2O and PPTS-catalyzed sulfate hydrolysis method has been developed.

ACCESSION NUMBER: 2000-619109 HCPLUS
 DOCUMENT NUMBER: 133:335356
 TITLE: A new mild PTSA-catalyzed method for sulfate ester hydrolysis and acid-catalyzed rearrangement of 12-acetyl-diene-11-ol tetracyclic triterpenoids involving an angular methyl migration


AUTHOR(S): Singh, S. B.
 CORPORATE SOURCE: Merck Research Laboratories, Rahway, NJ, 07065, USA
 SOURCE: Tetrahedron Letters (2000), 41(36), 6973-6976
 CODEN: TELEAY; ISSN: 0040-4039
 PUBLISHER: Elsevier Science Ltd.

DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 133:335356
 IT 304641-66-5P 304641-67-6P 304641-68-7P
 304641-71-2P

RL: SRN (Synthetic preparation); PREP (Preparation)
 (PTSA-catalyzed method for sulfate ester hydrolysis and acid-catalyzed rearrangement of 12-acetyl-diene-11-ol tetracyclic triterpenoids involving an angular Me migration)

RN 304641-67-6 HCPLUS
 CN 18-Norergosta-8,11,13,24(28)-tetraene-2,3-diol, 15-methoxy-4,4,12-trimethyl-, (2a,3b,5a)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 304641-67-6 HCPLUS
 CN 18-Norergosta-8,11,13,24(28)-tetraene-2,3-diol, 15-methoxy-4,4,12-trimethyl-, (2a,3b,5a)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L12 ANSWER 9 OF 15 HCPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 304641-68-7 HCPLUS
 CN 18-Norergosta-8,11,13,15,24(28)-pentaene-2,3-diol, 4,4,12-trimethyl-, (2a,3b,5a)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 304641-71-2 HCPLUS
 CN 18-Norergosta-8,8,11,13,24(28)-pentaene-2,3-diol, 4,4,12-trimethyl-, (2a,3b,5a)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L12 ANSWER 9 OF 15 HCPLUS COPYRIGHT 2006 ACS on STN (Continued)



REFERENCE COUNT: 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


L12 ANSWER 12 OF 15 HCAPLUS COPYRIGHT 2006 ACS on STN
 ED Entered STN: 12 May 1984
 GI For diagram(s), see printed CA Issue.
 AB The structure of 2,3-(ethylidenedioxy)cleistanthol (I) was determined by the X-ray diffraction technique.
 ACCESSION NUMBER: 1976:59769 HCAPLUS
 DOCUMENT NUMBER: 84:59769
 TITLE: Crystal and molecular structure of the 12-bromoacetate of 2,3-ethylidenedioxycleistanthol, an aromatic diterpene
 AUTHOR(S): Laing, Michael; Somerville, Polly
 CORPORATE SOURCE: Chem. Dep., Univ. Natal, Durban, S. Afr.
 SOURCE: Journal of the South African Chemical Institute (1975), 28(2), 279-80
 CODEN: JSACAT; ISSN: 0038-2078
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 IT 24465-21-2
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (stereochem. of)
 RN 24465-21-2 HCAPLUS
 CN 2,3,6-Phenanthrenetriol, 8-ethenyl-1,2,3,4a,9,10,10a-octahydro-1,1,4a,7-tetramethyl-, (2S,3R,4aR,10aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L12 ANSWER 13 OF 15 HCAPLUS COPYRIGHT 2006 ACS on STN
 ED Entered STN: 12 May 1984
 GI For diagram(s), see printed CA Issue.
 AB Cleistanthol, obtained from the heartwood of Cleistanthus schlechteri var schlechteri, is 13-methyl-14-vinyl-5 β ,10 α -podocarpa-8,11,13-triene-2 α ,3 α ,12-triol (I).
 ACCESSION NUMBER: 1971:112242 HCAPLUS
 DOCUMENT NUMBER: 74:112242
 TITLE: Constitution of the aromatic diterpene cleistanthol
 AUTHOR(S): Pegel, K. H.; McGarry, E. J.; Phillips, L.; Waight, E. S.
 CORPORATE SOURCE: Chem. Dep., Natal Univ., Durban, S. Afr.
 SOURCE: Journal of the Chemical Society [Section] C: Organic (1971), (5), 904-9
 CODEN: JSOAX; ISSN: 0022-4952
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 IT 24465-21-2P 24465-23-4P 24465-24-5P
 31560-91-5P 31560-94-8P 31570-35-1P
 31570-38-4P 31590-10-0P 31597-76-9P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of)
 RN 24465-21-2 HCAPLUS
 CN 2,3,6-Phenanthrenetriol, 8-ethenyl-1,2,3,4a,9,10,10a-octahydro-1,1,4a,7-tetramethyl-, (2S,3R,4aR,10aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 24465-23-4 HCAPLUS
 CN 5 β ,10 α -Podocarpa-8,11,13-triene-2 α ,3 α ,12-triol,
 14-ethyl-13-methyl- (8CI) (CA INDEX NAME)


Absolute stereochemistry.

L12 ANSWER 13 OF 15 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

RN 24465-24-5 HCAPLUS
 CN 5 β ,10 α -Podocarpa-8,11,13-trien-7-one, 14-ethyl-2 α ,3 α ,12-trihydroxy-13-methyl- (8CI) (CA INDEX NAME)

RN 31560-91-5 HCAPLUS
 CN 5 β ,10 α -Podocarpa-8,11,13-triene-2 α ,3 α -diol,
 12-methoxy-13-methyl-14-vinyl- (8CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 31560-94-8 HCAPLUS
 CN 5 β ,10 α -Podocarpa-8,11,13-triene-2 α ,3 α -diol,
 14-ethyl-12-methoxy-13-methyl- (8CI) (CA INDEX NAME)

Absolute stereochemistry.


L12 ANSWER 13 OF 15 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

RN 31570-35-1 HCAPLUS
 CN 5 β ,10 α -Podocarpa-8,11,13-triene-14-carboxylic acid,
 2 α ,3 α ,12-trihydroxy-13-methyl- (8CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 31570-38-4 HCAPLUS
 CN 5 β ,10 α -Podocarpa-8,11,13-triene-2 α ,3 α ,12-triol,
 14-(1-hydroxyethyl)-13-methyl- (8CI) (CA INDEX NAME)




RN 31590-10-0 HCAPLUS
 CN 5 β ,10 α -Podocarpa-8,11,13-triene-2 α ,3 α ,12-triol,
 13-methyl-14-vinyl-, 12-p-toluenesulfonate (8CI) (CA INDEX NAME)

Rotation (-). Absolute stereochemistry unknown.



RN 31597-76-9 HCAPLUS
 CN 5B,10a-Podocarpa-8,11,13-triene-14-carboxylic acid, 2a,3a,12-trihydroxy-13-methyl-, methyl ester (8CI) (CA INDEX NAME)

Rotation (-). Absolute stereochemistry unknown.




L12 ANSWER 14 OF 15 HCAPLUS COPYRIGHT 2006 ACS on STN
 ED Entered STN: 12 May 1984
 GI For diagram(s), see printed CA Issue.
 AB The structure of cleistanthol (I), m. 193-4°, [α]D -40° [D]OH₃ (triacetate m. 146-7°, [α]D -53°), was established. Reduction of I gave a dihydro derivative, m. 225°, [α]D -59°, the triacetate of which was oxidized to the 7-oxo-1,3,12-trihydroxy-8,11-13-triene, m. 239-40°, λ 236, 288 μm. Dehydrogenation of I gave 1-ethyl-2,8-dimethyl-3-phenanthrol, m. 138-9°. The position and configuration of the vicinal diol grouping was established by the reaction of the 12-Me ether of the dihydro dimerolate of I with NaI.

ACCESSION NUMBER: 1969-524711 HCAPLUS
 DOCUMENT NUMBER: 71:124711
 TITLE: Cleistanthol, a novel diterpene from Cleistanthus schlechteri (Euphorbiaceae)
 AUTHOR(S): McGarry, E. J.; Pegel, K. H.; Phillips, Leslie; Wright, Eric S.
 CORPORATE SOURCE: Natal Univ., Durban, S. Afr.
 SOURCE: Journal of the Chemical Society [Section] D: Chemical Communications (1969), (18), 1074
 CODEN: CGJDAO; ISSN: 0577-6171
 DOCUMENT TYPE: Journal
 LANGUAGE: English


IT 24465-21-2
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (as structure for (-)-cleistanthol)
 RN 24465-21-2 HCAPLUS
 CN 2,3,6-Phenanthrenetriol, 8-ethenyl-1,2,3,4,4a,9,10,10a-octahydro-1,1,4a,7-tetramethyl-, (2S,3R,4aR,10aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 24465-23-4P 24465-24-5P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of)
 RN 24465-23-4 HCAPLUS
 CN 5B,10a-Podocarpa-8,11,13-triene-2a,3a,12-triol, 14-ethyl-13-methyl- (8CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 24465-24-5 HCAPLUS
 CN 5B,10a-Podocarpa-8,11,13-trien-7-one, 14-ethyl-2a,3a,12-trihydroxy-13-methyl- (8CI) (CA INDEX NAME)



L12 ANSWER 15 OF 15 HCAPLUS COPYRIGHT 2006 ACS on STN
 ED Entered STN: 22 Apr 2001
 AB The location of the Me group in methyldihydrocodeinone (I) and -morphinone is still unknown and any attempt to ascertain it through a degradation to a dimethoxymethylphenanthrene must include its passing through a nuclear Me derivative of the type of 3-methoxy-4-hydroxy-6-keto-13-ethyloctahydrophenanthrene, with subsequent conversion into a completely aromatic system. Because rearrangement or loss of MeO or alkyl may occur, this route is unsuitable. The opening of ring 3, however, should lead to a substituted tetrahydronaphthalene derivative which could be identified by unequivocal synthesis. Such a way would simultaneously prove the point of attachment of the ethanamine chain. Because I is too costly to try out this type of degradation and I can be converted to a nuclear methylated dihydrotetrahydronaphthalene derivative which could be identified by model substance. Refluxing 150 g. II in 1.4 l. MeOH with 86 g. MeI 45 min., concentrating the solution to about 0.5 l., adding 600 cc. H₂O and 800

cc. 10% NaOH, heating the mixture 2 h. on a steam bath, and cooling give 87% des-N-methyl dihydrotetrahydronaphthalene (III), m. 136.5-8°. Slowly adding 21 cc. MeI to 90 g. III in 750 cc. Me₂CO and warming the mixture gently 0.5 h. give 95% III methiodide (IV), m. 241-3°. Gradually treating 50 g. finely powdered IV in 200 cc. H₂O over a period of 0.5 h. with 600 cc. 0.18 N TlOH, heating the mixture 0.5 h. on a steam bath, and evaporating the filtered solution in vacuo to dryness give 40 g. III methohydroxide (V). Heating V in 10-g. batches at 120°/0.6 mm. gives 23.5 g. sublimate which is dissolved in 900 cc. ether, the solution extracted with 0.25 N HCl until free

of N, and the washed and dried ether solution evaporated, giving 60% 6-methoxy-13-vinyltetrahydronaphenol Me ether (VI), m. 123-4.5°. From the HCl solution 4 g. III, m. 134-6°, is recovered. Hydrogenating 17.5 g. VI in 500 cc. 95% EtOH in the presence of 1.8 g. Pd-CaCO₃ 2.5 h. gives 17.3 g. 6-methoxy-13-ethylhexahydromorphol Me ether (VII), subliming at 130°/0.4 mm. m. 65-6.5°, [α]D₂₀ -134° (c 0.41, EtOH). Adding within 50 min. 60 g. Na to 17.7 g. VII in 250 cc. boiling and stirred EtOH, with intermittent addition of eleven 50-cc. batches of EtOH, heating the mixture another hr., cautiously adding ice H₂O, evaporating in vacuo, taking up the residue in ether, and evaporating the washed (H₂O, NaHSO₃) and dried ether solution give

16.6 g. oily crystals which are treated 1 h. in 250 cc. warm EtOH with 45 cc. concentrated HCl, concentrated in vacuo to incipient crystallization, diluted with H₂O, and kept overnight, giving 53% 3-methoxy-4-hydroxy-6-keto-4b-ethyloctahydrophenanthrene (VIII), m. 151-3°, subliming at 160-70°/0.5 mm., m. 154-5.5°, [α]D₂₀ -48° (c 0.25, EtOH). Reducing of 8 g. VII in 175 cc. EtOH with 32.5 g. Na, diluting the mixture with 200 cc. EtOH, saturating it with CO₂, and concentrating the filtered

EtOH solution in vacuo in a N atmospheric give 2.5 g. 3-methoxy-4-hydroxy-4b-ethyloctahydrophenanthrene 8,6,7-Me enolate (IX), prisms from MeOAc,

subliming at 140-50°/0.5 mm., m. 171-3°, [α]D₂₀ 23.8° (c 0.34, EtOH); it gives an emerald-green color with FeCl₃.

Concentration of the mother liquors and evaporatively distilling the residue give

another 0.75 g. IX, m. 163-6°. Hydrolysis of IX gives VIII.

Treating 11.3 g. VIII in 350 cc. 60% EtOH within 10 min. with 49 cc. Me₂SO₄ in a N atmospheric with stirring, refluxing the mixture 18 h., adding

58 g. KOH in 75 cc. H₂O, refluxing the mixture another 0.5 h., extracting it with


ether, and evaporating the washed (2 N NaOH, 2 N HCl, H₂O) ether extract give

11 g. 3,4-dimethoxy-6-keto-4b-ethyloctahydrophenanthrene (X), subliming at

L12 ANSWER 15 OF 15 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 115-20'/0.5 mm., m. 114-16°, [a]D20 -54.2° (c 0.5, EtOH) (semicarbazone, needles from Me2CO, m. 203.5-5°). Heating 55 g. X, 42 g. Na2HCl, and 48 g. NaOAc in 260 cc. MeOH and 50 cc. H2O 5.5 h. on a steam bath, concg. the soln. in vacuo, adding 750 cc. H2O, and extg. With ether give 50 g. Y oxime (XI) (a mixt. of diastereoisomers) as a sirup. Hydrogenating 60 g. XI in 500 cc. AcOH in the presence of 4.5 g. PtO2 3.25 h., making the mixt. alk. with NH4OH at 0°, extg. with ether, and treating the ether ext. with HCl-EtOH at 0°, give 40 and 16 g. of mixts. of α - (XII) and β - (XIII) isomers. Crystn. of the 1st crop from Me2CHOH gives 34.7 g. XII, slender prisms, m. 138-140°, [a]D20 -113°, [a]D20 12.4° (c 0.8, H2O) (perchlorate, plates, m. 197.5-8°, [a]D20 0.8° (c 0.36, EtOH)). Concn. of the Me2CHOH mother liquor and diln. with Me2CO give 4.6 g. XIII, fine needles, m. 252-5°, [a]D20 56.3° (c 0.74, H2O). Crystn. of the 2nd crop from Me2CHOH gives 11.5 g. XIII, m. 251-3°, [a]D20 58.9° (c 0.74, H2O) (perchlorate, small prisms, m. 238-9.5°, [a]D20 -63.8° (c 0.92, EtOH)). Heating 27.4 g. free XII with 18.8 cc. 98% HCO2H and 17.7 cc. eq. 36% HCHO 4.5 h. on a steam bath, dilg. the mixt. with H2O, acidifying it with 100 cc. 2 N HCl, washing it with ether, and making the acid soln. alk. with NH4OH give 25 g. of a yellow sirup which, for the removal of primary and secondary bases, is shaken in 300 cc. ether with 15 cc. BzCl and 275 cc. 2 N NaOH, the ether soln. washed with H2O, extd. with 0.2 N HCl, and the washed (ether) acid soln. neutralized with NH4OH and extd. with ether, giving 85% α -3,4-dimethoxy-6-dimethylamino-4b-ethyloctahydrophenanthrene, (XIV), subliming at 120-30°/0.4 mm., m. 76.5-8° (perchlorate (XV), prismatic needles, m. 224-6.5°, [a]D20 18.8° (c 0.93, EtOH)). Methiodide (XVI), prep'd. by refluxing 23.3 g. XIV in 50 cc. Me2CO with 8.0 cc. Mei 0.5 h., m. 242-4°). Methylation of 6-Me2N deriv., b.06. XIII in the same way and treating the free 6-Me2N deriv., b.06. 140-50°, with alc. HClO4 give the β -isomer of XV, small flat prisms, m. 230-1.5°, [a]D20 -64.3° (c 0.9, EtOH); β -methiodide (XVII), m. 263-4°. Gradually treating 12 g. finely poud. XVI in 50 cc. H2O with 190 cc. 0.16 N ThOH, heating the mixt. 20 min. on a steam bath, evapg. the filtered soln. in vacuo, and decopg. the residual sirup by evaporative distn. at 140°/0.4 mm. give a semisolid distillate which, shaken in ether with 0.2 N HCl and the ether soln., evapd., gives 88% (based on the recovered XVI) 3,4-dimethoxy-4b-Et- Δ 5(ox, 6)-hexahydrophenanthrene (XVIII), massive prisms, m. 110.5-12°, [a]D20 6.8° (c 0.8, EtOH). Making the HCl soln. alk. gives 5.2 g. XIV. XVIII is also obtained from XVII. Hydrogenating 0.4 g. XVIII in 20 cc. MeOH with 80 mg. PtO2 6 min. gives 0.35 g. of the octahydro compd., m. 78.5-80°, [a]D20 -32.0° (c 0.4, EtOH). Adding 5 cc. XVIII in 130 cc. ether to 4.8 g. OsO4 in 3.1 cc. anhyd. C5HSn at 0° and keeping the mixt. 15 h. at 0° give 83% adduct (XIX). Shaking XIX in 100 cc. CH2Cl2 with 3.7 g. KOH and 9.6 g. mannitol in 300 cc. 70 min. with intermittent cooling, extg. the mixt. with CH2Cl2 and evapg. the washed (0.25 N HCl) and dried CH2Cl2 soln. give 4.9 g. glycol mixt. which, dissolved in 500 cc. ether and the filtered soln. concd. to incipient crystn., gives 1.9 g. α -3,4-dimethoxy-5,6-(or 6,7-)dihydroxy-4b-ethyloctahydrophenanthrene (XX), prisms, m. 150.5-2°, [a]D20 -47.6° (c 0.6, EtOH). The ether soln. liquors yield 1.3 g. β -isomer, m. 119-21°, [a]D20 -11.7° (c 1, EtOH). Adding 0.61 g. Pb(OAc)4 during 5 min. to 0.42 g. XX in 25 cc. dry C6H6 with stirring, stirring another 15 min., evapg. the filtered, washed

L12 ANSWER 15 OF 15 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 (0.25% NaHCO3, cold H2O), and dried C6H6 soln. in vacuo, dissolving the residue in 10 cc. dry ether, adding the ice-cold soln. to 0.46 g. EtSH, 0.1 g. fused 2nCl2, and 0.07 g. anhyd. Na2S04 at 0°, keeping the mixt. 19 h. at 0°, pouring it into 10 cc. ice H2O, extg. it with ether, concg. the washed (H2O, 2 N NaOH, H2O) ether soln., refluxing the residue in 70 cc. 70% EtOH with 10 g. Raney Ni 2.5 h., concg. the filtered soln. in vacuo, and extg. the residue with ether give 0.28 g. oily crystals which, triturated with ether-petr. ether (4:1), yield a compd., C18H26O4, slender prisms, m. 158-60°, of the same compn. as XX but giving a marked m.p. depression with it. Concn. of the ether-petr. ether soln. in vacuo gives 0.22 g. 1,1,2-triethyl-7,8-dimethoxy-1,2,3,4-tetrahydronaphthalene (?) (XXI), b.0.4 96-105°, d2020 1.027, D20 1.5295, MR 80.61, [a]D20 -53° (c 0.93, EtOH). Degradn. of the β -isomer of XX give an oil, b.0.4 95-108°, D20 1.5288, [a]D20 1.5288, -61° (c 1, EtOH), having the same IR absorption spectrum as XXI.

ACCESSION NUMBER: 195220579 HCAPLUS
 DOCUMENT NUMBER: 46:20579
 ORIGINAL REFERENCE NO.: 46:3542e-i,3543a-i,3544a-d
 TITLE: Structure studies in the morphine series. Degradation of dihydrothebaine to a dimethoxytrisalkyltetrahydronaphthalene
 AUTHOR(S): Sargent, Lewis J.; Small, Lyndon F.
 CORPORATE SOURCE: Natl. Inst. of Health, Bethesda, MD
 SOURCE: Journal of Organic Chemistry (1951), 16, 1031-40
 DOCUMENT TYPE: CODEN: JOCEAH; ISSN: 0022-3263
 LANGUAGE: Journal
 OTHER SOURCE(S): Unavailable
 IT CASREACT 46:20579
 855695-17-9, 2,3-Phenanthrenediol, 4a-ethyl-1,2,3,4,4a,9,10,10a-octahydro-5,6-dimethoxy-
 (isomers)
 RN 855695-17-9 HCAPLUS
 CN 2,3-Phenanthrenediol, 4a-ethyl-1,2,3,4,4a,9,10,10a-octahydro-5,6-dimethoxy-
 (5CI) (CA INDEX NAME)



10615126amend

=> log y

COST IN U.S. DOLLARS

	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	117.13	871.33

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-11.25	-43.50

STN INTERNATIONAL LOGOFF AT 14:39:07 ON 21 MAR 2006

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTANAG1626

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

NEWS 1	Web Page URLs for STN Seminar Schedule - N. America	
NEWS 2	"Ask CAS" for self-help around the clock	
NEWS 3	DEC 21	IPC search and display fields enhanced in CA/CAplus with the IPC reform
NEWS 4	DEC 23	New IPC8 SEARCH, DISPLAY, and SELECT fields in USPATFULL/USPAT2
NEWS 5	JAN 13	IPC 8 searching in IFIPAT, IFIUDB, and IFICDB
NEWS 6	JAN 13	New IPC 8 SEARCH, DISPLAY, and SELECT enhancements added to INPADOC
NEWS 7	JAN 17	Pre-1988 INPI data added to MARPAT
NEWS 8	JAN 17	IPC 8 in the WPI family of databases including WPIFV
NEWS 9	JAN 30	Saved answer limit increased
NEWS 10	JAN 31	Monthly current-awareness alert (SDI) frequency added to TULSA
NEWS 11	FEB 21	STN AnaVist, Version 1.1, lets you share your STN AnaVist visualization results
NEWS 12	FEB 22	Status of current WO (PCT) information on STN
NEWS 13	FEB 22	The IPC thesaurus added to additional patent databases on STN
NEWS 14	FEB 22	Updates in EPFULL; IPC 8 enhancements added
NEWS 15	FEB 27	New STN AnaVist pricing effective March 1, 2006
NEWS 16	FEB 28	MEDLINE/LMEDLINE reload improves functionality
NEWS 17	FEB 28	TOXCENTER reloaded with enhancements
NEWS 18	FEB 28	REGISTRY/ZREGISTRY enhanced with more experimental spectral property data
NEWS 19	MAR 01	INSPEC reloaded and enhanced
NEWS 20	MAR 03	Updates in PATDPA; addition of IPC 8 data without attributes
NEWS 21	MAR 08	X.25 communication option no longer available after June 2006
NEWS EXPRESS	FEBRUARY 15 CURRENT VERSION FOR WINDOWS IS V8.01a, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 19 DECEMBER 2005. V8.0 AND V8.01 USERS CAN OBTAIN THE UPGRADE TO V8.01a AT http://download.cas.org/express/v8.0-Discover/	
NEWS HOURS	STN Operating Hours Plus Help Desk Availability	
NEWS LOGIN	Welcome Banner and News Items	

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

FILE 'HOME' ENTERED AT 14:16:17 ON 21 MAR 2006

FILE 'REGISTRY' ENTERED AT 14:16:35 ON 21 MAR 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 20 MAR 2006 HIGHEST RN 877371-73-8
DICTIONARY FILE UPDATES: 20 MAR 2006 HIGHEST RN 877371-73-8

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 6, 2006

Please note that search-term pricing does apply when conducting SmartSELECT searches.



```
*****  
*  
* The CA roles and document type information have been removed from *  
* the IDE default display format and the ED field has been added, *  
* effective March 20, 2005. A new display format, IDERL, is now *  
* available and contains the CA role and document type information. *  
*  
*****
```

Structure search iteration limits have been increased. See **HELP SLIMITS** for details.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/regprops.html>

=>
Uploading C:\Program Files\Stnexp\Queries\10615126Amend.str



chain nodes :

10615126amend

16 18 20 21 23 25
ring nodes :
1 2 3 4 5 6 7 8 9 10 11 12 13 14
chain bonds :
7-18 12-21 12-23 13-20 13-25
ring bonds :
1-2 1-6 1-10 2-3 3-4 4-5 5-6 6-7 7-8 7-11 8-9 8-14 9-10 11-12 12-13 13-14
exact/norm bonds :
1-10 6-7 7-8 7-11 7-18 8-9 8-14 9-10 11-12 12-13 12-21 12-23 13-14 13-20
13-25
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6

G1:X,Ak,H

G2:Ak,Ph

G3:N,OH

G4:Cy,Ak


Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom 11:Atom
12:Atom 13:Atom 14:Atom 16:CLASS 17:CLASS 18:CLASS 20:CLASS 21:CLASS 23:CLASS
25:CLASS

L1 STRUCTURE UPLOADED

=> d 11

L1 HAS NO ANSWERS

L1 STR



G1 X,Ak,H

G2 Ak,Ph

G3 N,OH

G4 Cy,Ak

Structure attributes must be viewed using STN Express query preparation.

=> s 11

SAMPLE SEARCH INITIATED 14:17:46 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 15855 TO ITERATE

12.6% PROCESSED 2000 ITERATIONS
 INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
 SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
 BATCH **COMPLETE**
 PROJECTED ITERATIONS: 309559 TO 324641
 PROJECTED ANSWERS: 0 TO 0

L2 0 SEA SSS SAM L1

=> s 11 full
 FULL SEARCH INITIATED 14:17:50 FILE 'REGISTRY'
 FULL SCREEN SEARCH COMPLETED - 315888 TO ITERATE

100.0% PROCESSED 315888 ITERATIONS 85 ANSWERS
 SEARCH TIME: 00.00.04

L3 85 SEA SSS FUL L1

=> fil hcplus
 COST IN U.S. DOLLARS SINCE FILE TOTAL
 FULL ESTIMATED COST ENTRY SESSION
 167.82 168.03

FILE 'HCAPLUS' ENTERED AT 14:18:06 ON 21 MAR 2006
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
 COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 21 Mar 2006 VOL 144 ISS 13
 FILE LAST UPDATED: 20 Mar 2006 (20060320/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s 13
 L4 2 L3

=> d ed abs ibib hitstr 1-2

L4 ANSWER 1 OF 2 HCPLUS COPYRIGHT 2006 ACS on STN
ED Entered STN: 27 May 2005
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The invention relates to a preparation of octahydrophenanthrenecarboxylic acid hydrazide derivs. of formula I (wherein: R1 is 1 to 6 independent substituents; R2 is 1 or 2 independent substituents selected from H, alkyl optionally substituted with 1-3 halogens, alkenyl, or OH, etc.; R3 is heterocycle), useful as glucocorticoid receptor modulators. The invention compds. are useful in the treatment of obesity, diabetes, anxiety, or inflammatory diseases. For instance, octahydrophenanthrenecarboxylic acid hydrazide derivative II was prepared from naphthalene derivative III in 9 steps.

Preferred invention compds. showed ED50 less than 3 μ M.

ACCESSION NUMBER: 20051451357 HCPLUS

DOCUMENT NUMBER: 143:7512

TITLE: A preparation of octahydrophenanthrenecarboxylic acid hydrazide derivatives, useful as glucocorticoid receptor modulators

INVENTOR(S): Robinson, Ralph Peiton, Jr.; Kleinman, Edward Fox; Cheng, Hengniao

PATENT ASSIGNEE(S): Pfizer Products Inc., USA

SOURCE: PCT Int. Appl., 44 pp.

CODEN: PIXKD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005047254	Al	20050526	WO 2004-IB3671	20041108
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, C2, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NE, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SV, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW A2, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				

PRIORITY APPLN. INFO.: US 2003-519937P P 20031113

OTHER SOURCE(S): MARPAT 143:7512

IT 852403-63-5P


RL: PAC (pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); B10 (Biological study); PREP (Preparation); USES (Uses)

(preparation of octahydrophenanthrenecarboxylic acid hydrazide derivs. useful as glucocorticoid receptor modulators)

RN 852403-63-5 HCPLUS


CN 2-Phenanthrenecarboxylic acid, 4b-ethyl-4b,5,6,7,8,8a,9,10-octahydro-6,7-dihydroxy-6-methyl-7-(2-thiazolyl)-, 2-(2-pyridinyl)hydrazide,

L4 ANSWER 1 OF 2 HCPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 852403-65-7 HCPLUS
CN 2-Phenanthrenecarboxylic acid, 4b-ethyl-4b,5,6,7,8,8a,9,10-octahydro-6,7-dihydroxy-6-methyl-7-(2-thiazolyl)-, methyl ester, (4bR,6R,7R,8aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 852403-66-8 HCPLUS
CN 2-Phenanthrenecarboxylic acid, 4b-ethyl-4b,5,6,7,8,8a,9,10-octahydro-6,7-dihydroxy-6-methyl-7-(2-thiazolyl)-, (4bR,6R,7R,8aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE REFORMAT

L4 ANSWER 1 OF 2 HCPLUS COPYRIGHT 2006 ACS on STN (Continued)
(4bR,6R,7R,8aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 645398-33-0P 852403-64-6P 852403-65-7P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of octahydrophenanthrenecarboxylic acid hydrazide derivs. useful as glucocorticoid receptor modulators)

RN 645398-33-0 HCPLUS

CN 2,3,7-Phenanthrenetriol, 4a-ethyl-1,2,3,4,4a,9,10,10a-octahydro-3-methyl-2-(2-thiazolyl)-, (2R,3R,4aR,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.





RN 852403-64-6 HCPLUS

CN 2,3,7-Phenanthrenetriol, 4a-ethyl-1,2,3,4,4a,9,10,10a-octahydro-3-methyl-2-(2-thiazolyl)-, 7-methanesulfonate, (2R,3R,4aR,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 2 OF 2 HCPLUS COPYRIGHT 2006 ACS on STN
ED Entered STN: 18 Jan 2004
GI



AB Title compds. I [wherein A = CR6R7CR8R9, COCR10R11, or CR12=CR13; X and Y = independently H, F, Cl, Br, or alkyl; R1 = alkyl, alkenyl, or (un)substituted benzyl; R2 = (un)substituted (cyclo)alkyl(alkyl), alkenyl, alkynyl, (hetero)aryl(alkyl), or heterocyclyl(alkyl); R3 = H or (un)substituted (cyclo)alkyl, alkenyl, alkynyl, heterocyclyl, or (hetero)aryl; R4 = OH or NR14R15; R5 = H, halo, OH, CN, or (un)substituted (cyclo)alkyl(oxy), alkenyl, alkynyl, (hetero)aryl(oxy), heterocyclyl(oxy), carbamoyl, sulfamoyl, acyl(oxy), etc.; R6-R9 independently H, alkyl, F, or OH; R10 and R11 = independently H or alkyl; R12 and R13 independently H, F, or alkyl; R14 and R15 = independently H or alkyl; and pharmaceutically acceptable salts thereof] were prepared as glucocorticoid receptor agonists (no data). For example, (3S,4aR,10aR)-3-hydroxy-4a-ethyl-7-hydroxy-3,4a,9,10,10a-hexahydro-1H-phenanthren-2-one (multi-step preparation given) was treated with NaOH in DMF and H2O followed by 0.2M HCl to give a 2:1 mixture of the 2-keto-3-hydroxy and 2-hydroxy-3-keto derivs. The 2-keto enriched compound (9:1 ratio of 2-keto to 3-keto derivative) was alkylated with propyne in THF using BuLi in hexane to afford II (25%). Bioassays for glucocorticoid receptor modulation and antiinflammatory response are described, but no specific data are provided. Thus, I and their pharmaceutical compns., salts, and prodrugs are useful in the treatment of certain inflammatory disorders, endocrine disorders, collagen diseases, dermatol. diseases, allergic states, ophthalmic diseases, respiratory diseases, hematol. disorders, neoplastic diseases, edematous states, and gastrointestinal diseases (no data).
ACCESSION NUMBER: 200414124 HCPLUS
DOCUMENT NUMBER: 140:111136
TITLE: Preparation of octahydrophenanthrenols as glucocorticoid receptor modulators for treatment of inflammatory conditions

INVENTOR(S): Chantigny, Yves Andje; Kleinman, Edward Fox; Robinson, Ralph Peiton, Jr.

PATENT ASSIGNEE(S): Pfizer Products Inc., USA

SOURCE: PCT Int. Appl., 143 pp.

CODEN: PIXKD2
DOCUMENT TYPE: Patent

L4 ANSWER 2 OF 2 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004005229	A1	20040115	WO 2003-IB2941	20030625
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KG, KP, KR, LS, LT, LU, LV, MA, MD, MG, MK, MW, MX, MZ, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TT, TZ, UA, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: GH, GM, KE, LS, MW, SD, SL, TZ, UG, ZM, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GO, GW, ML, MR, NE, SN, TD, TG				
CA 2491994	AA	20040115	CA 2003-2491994	20030625
AU 2003281355	A1	20040123	AU 2003-281355	20030625
EP 1521733	A1	20050413	EP 2003-740911	20030625
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AD, BG, CZ, EE, HU, SK				
BR 2003012575	A	20050503	BR 2003-12575	20030625
JP 2005532389	T2	20051027	JP 2004-519100	20030625
US 2004138262	A1	20040715	US 2003-615126	20030708
PRIORITY APPLN. INFO.:			US 2002-394425P	P 20020708
			WO 2003-IB2941	W 20030625


OTHER SOURCE(S): MARPAT 140:111136

IT 645397-62-28 HCAPLUS
 645397-62-2P 645397-64-4P 645397-82-5P
 645397-83-7P 645397-84-8P 645397-85-9P
 645397-86-0P 645397-87-1P 645397-89-3P
 645398-25-09 645398-29-4P (2R,3R,4A,10aS)-4a-Ethyl-2,3,7-trihydroxy-3-methyl-2-(pyridin-2-yl)-2,3,4,4a,10,10a-hexahydro-1H-phenanthren-9-one 645398-39-6P
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (glucocorticoid receptor modulator; preparation of octahydrophenanthrenols as glucocorticoid receptor modulators for treatment of inflammatory conditions)

RN 645397-62-2 HCAPLUS

CN 2,3,7-Phenanthrenetriol, 4a-ethyl-1,2,3,4,4a,9,10,10a-octahydro-3-methyl-1-phenyl-, (2R,3R,4A,10aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 645397-64-4 HCAPLUS

L4 ANSWER 2 OF 2 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 6,7-dihydroxy-6-methyl-7-phenyl-2-phenanthrenyl]oxy)-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 645397-85-9 HCAPLUS

CN Acetonitrile, [(4bR,6R,7R,8aR)-4b-ethyl-4b,5,6,7,8,8a,9,10-octahydro-6,7-dihydroxy-6-methyl-7-phenyl-2-phenanthrenyl]oxy)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 645397-86-0 HCAPLUS

CN Butanenitrile, 4-[(4bR,6R,7R,8aR)-4b-ethyl-4b,5,6,7,8,8a,9,10-octahydro-6,7-dihydroxy-6-methyl-7-phenyl-2-phenanthrenyl]oxy)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 645397-87-1 HCAPLUS

CN Pentanenitrile, 5-[(4bR,6R,7R,8aR)-4b-ethyl-4b,5,6,7,8,8a,9,10-octahydro-6,7-dihydroxy-6-methyl-7-phenyl-2-phenanthrenyl]oxy)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 2 OF 2 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 CN 9(1H)-Phenanthrenone, 4a-ethyl-2,3,4,4a,10,10a-hexahydro-2,3,7-trihydroxy-3-methyl-2-(pyridin-2-yl)-, (2R,3R,4aR,10aS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 645397-82-6 HCAPLUS

CN Acetic acid, [(4bR,6R,7R,8aR)-4b-ethyl-4b,5,6,7,8,8a,9,10-octahydro-6,7-dihydroxy-6-methyl-7-phenyl-2-phenanthrenyl]oxy)-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 645397-83-7 HCAPLUS

CN Butanoic acid, 4-[(4bR,6R,7R,8aR)-4b-ethyl-4b,5,6,7,8,8a,9,10-octahydro-6,7-dihydroxy-6-methyl-7-phenyl-2-phenanthrenyl]oxy)-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 645397-84-8 HCAPLUS

CN Pentanoic acid, 5-[(4bR,6R,7R,8aR)-4b-ethyl-4b,5,6,7,8,8a,9,10-octahydro-


L4 ANSWER 2 OF 2 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 645397-89-3 HCAPLUS

CN Acetic acid, [(4bR,6R,7R,8aR)-4b-ethyl-4b,5,6,7,8,8a,9,10-octahydro-6,7-dihydroxy-6-methyl-7-phenyl-2-phenanthrenyl]oxy)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 645398-25-0 HCAPLUS

CN Acetonitrile, [(4bR,6R,7R,8aR)-4b-ethyl-4b,5,6,7,8,8a,9,10-octahydro-6,7-dihydroxy-6-methyl-7-(2-pyridinyl)-2-phenanthrenyl]oxy)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 645398-29-4 HCAPLUS


CN 9(1H)-Phenanthrenone, 4a-ethyl-2,3,4,4a,10,10a-hexahydro-2,3,7-trihydroxy-3-methyl-2-(pyridin-2-yl)-, (2R,3R,4aR,10aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 645398-39-6 HCPLUS
CN Ethenane, 1-[(4bR,6R,7R,8aR)-4b-ethyl-4b,5,6,7,8,8a,9,10-octahydro-6,7-dihydroxy-6-methyl-7-phenyl-2-phenanthrenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 645397-63-3P 645397-65-5P 645397-66-6P
645397-67-7P 645397-68-8P 645397-69-9P
645397-70-2P 645397-72-4P 645397-73-5P
645397-74-6P 645397-75-7P 645397-77-9P
645397-78-0P 645397-79-1P 645397-80-4P
645397-81-5P 645397-88-2P 645397-90-6P
645397-91-7P 645397-92-8P 645397-93-9P
645397-94-0P 645397-95-1P 645397-96-2P
645397-97-3P 645397-98-4P 645397-99-5P
645398-00-1P 645398-01-2P 645398-02-3P
645398-03-4P 645398-04-5P 645398-05-6P
645398-06-7P 645398-07-8P 645398-08-9P
645398-09-0P 645398-10-3P 645398-11-4P
645398-12-5P 645398-13-6P 645398-14-7P
645398-15-8P 645398-16-9P 645398-17-0P
645398-18-1P, (2R,3R,4aR,10aR)-4a-Ethyl-3-methyl-2-(pyridin-2-yl)-1,2,3,4,4a,9,10,10a-octahydrophenanthrene-2,3,7-triol 645398-19-2P
645398-20-6P 645398-23-8P, (2R,3R,4aR,10aR)-4a-Ethyl-3-methyl-7-[(2-methylpyridin-3-yl)methoxy]-2-(pyridin-2-yl)-1,2,3,4,4a,9,10,10a-octahydrophenanthrene-2,3-diol 645398-24-9P
645398-26-1P, (2R,3R,4aR,10aR)-7-[(5-(2-(acetidin-1-yl)ethyl)-[1,2,4]oxadiazol-3-yl)methyl]oxy)-4a-Ethyl-3-methyl-2-(pyridin-2-yl)-1,2,3,4,4a,9,10,10a-octahydrophenanthrene-2,3-diol 645398-27-2P
645398-28-3P, (2R,3R,4aR,10aR)-7-[(5-(2-Dimethylaminoethyl)-[1,2,4]oxadiazol-3-yl)methyl]oxy)-4a-Ethyl-3-methyl-2-(pyridin-2-yl)-


645398-33-5P 645398-34-1P 645398-36-3P
645398-37-4P 645398-40-9P 645398-42-1P
645398-43-2P, (2R,3R,4aR,10aR)-2-Benzyl-4a-Ethyl-3-methyl-1,2,3,4,4a,9,10,10a-octahydrophenanthrene-2,3,7-triol 645398-46-5P
645398-47-6P 645398-48-7P 645398-49-8P
645398-50-1P, (2R,3R,4aR,10aR)-4a-Ethyl-3-methyl-2-prop-1-ynyl-1,2,3,4,4a,9,10,10a-octahydrophenanthrene-2,3,7-triol 645398-51-2P
645398-53-4P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses);
(glucocorticoid receptor modulator; prepn. of octahydrophenanthrenols as glucocorticoid receptor modulators for treatment of inflammatory conditions)

RN 645397-63-3 HCPLUS

CN 2,3,7-Phenanthrenetriol, 4a-ethyl-1,2,3,4,4a,9,10,10a-octahydro-3-methyl-2-phenyl-, (2R,3S,4aR,10aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 645397-65-5 HCPLUS

CN 2,3,7-Phenanthrenetriol, 4a-ethyl-1,2,3,4,4a,10a-hexahydro-3,9-dimethyl-2-phenyl-, (2R,3S,4aR,10aS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 645397-66-6 HCPLUS


CN 2,3,7-Phenanthrenetriol, 4a-ethyl-1,2,3,4,4a,10a-hexahydro-3,9-dimethyl-2-phenyl-, (2R,3R,4aR,10aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 645397-67-7 HCPLUS
CN 9(1H)-Phenanthrenone, 4a-Ethyl-2,3,4,4a,10,10a-hexahydro-2,3,7-trihydroxy-3-methyl-2-phenyl-, (2R,3S,4aR,10aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 645397-68-8 HCPLUS
CN 2,3,7-Phenanthrenetriol, 3,4a-Diethyl-1,2,3,4,4a,9,10,10a-octahydro-2-phenyl-, (2R,3R,4aR,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 645397-69-9 HCPLUS
CN 2,3,7-Phenanthrenetriol, 4a-Ethyl-1,2,3,4,4a,9,10,10a-octahydro-3-(1-methylethyl)-2-phenyl-, (2R,3S,4aR,10aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 645397-70-2 HCPLUS

CN 2,3,7-Phenanthrenetriol, 3-cyclopropyl-4a-Ethyl-1,2,3,4,4a,9,10,10a-octahydro-2-phenyl-, (2R,3S,4aR,10aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 645397-72-4 HCPLUS

CN 2,3,7-Phenanthrenetriol, 3-Ethynyl-4a-Ethyl-1,2,3,4,4a,9,10,10a-octahydro-2-phenyl-, (2R,3S,4aR,10aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 645397-73-5 HCPLUS


CN 2,3,7-Phenanthrenetriol, 4a-Ethyl-3-Ethynyl-1,2,3,4,4a,9,10,10a-octahydro-2-phenyl-, (2R,3S,4aR,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 645397-74-6 HCAPLUS
CN 2,3,7-Phenanthrenetriol, 2-cyclopropyl-4a-ethyl-1,2,3,4,4a,9,10,10a-octahydro-3-methyl-, (2R,3R,4aR,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 645397-75-7 HCAPLUS
CN 2,3,7-Phenanthrenetriol, 2-cyclopropyl-4a-ethyl-1,2,3,4,4a,9,10,10a-octahydro-3-phenyl-, (2R,3S,4aR,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 645397-77-9 HCAPLUS
CN 2,3-Phenanthrenetriol, 4a-ethyl-1,2,3,4,4a,9,10,10a-octahydro-3-methyl-7-[(2-methyl-3-pyridinyl)methoxy]-2-phenyl-, (2R,3R,4aR,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 645397-81-5 HCAPLUS
CN 2,3-Phenanthrenediol, 4a-ethyl-1,2,3,4,4a,9,10,10a-octahydro-7-(4-hydroxybutoxy)-3-methyl-2-phenyl-, (2R,3R,4aR,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 645397-88-2 HCAPLUS
CN Acetamide, 2-[(4bR,6R,7R,8aR)-4b-ethyl-4b,5,6,7,8,8a,9,10-octahydro-6,7-dihydroxy-6-methyl-7-phenyl-2-phenanthrenyl]oxy)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 645397-90-6 HCAPLUS
CN Butanoic acid, 4-[(4bR,6R,7R,8aR)-4b-ethyl-4b,5,6,7,8,8a,9,10-octahydro-6,7-dihydroxy-6-methyl-7-phenyl-2-phenanthrenyl]oxy)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 645397-78-0 HCAPLUS
CN 2,3-Phenanthrenediol, 4a-ethyl-1,2,3,4,4a,9,10,10a-octahydro-7-methoxy-3-methyl-2-phenyl-, (2R,3R,4aR,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 645397-79-1 HCAPLUS
CN 2,3-Phenanthrenediol, 4a-ethyl-1,2,3,4,4a,9,10,10a-octahydro-7-(2-hydroxyethoxy)-3-methyl-2-phenyl-, (2R,3R,4aR,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 645397-80-4 HCAPLUS
CN 2,3-Phenanthrenediol, 4a-ethyl-1,2,3,4,4a,9,10,10a-octahydro-7-(3-hydroxypropoxy)-3-methyl-2-phenyl-, (2R,3R,4aR,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 645397-91-7 HCAPLUS
CN Pentanoic acid, 5-[(4bR,6R,7R,8aR)-4b-ethyl-4b,5,6,7,8,8a,9,10-octahydro-6,7-dihydroxy-6-methyl-7-phenyl-2-phenanthrenyl]oxy)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 645397-92-8 HCAPLUS
CN 2,3-Phenanthrenediol, 4a-ethyl-1,2,3,4,4a,9,10,10a-octahydro-7-(2-hydroxybutoxy)-3-methyl-2-phenyl-, (2R,3R,4aR,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 645397-93-9 HCAPLUS
CN Butanoic acid, 4-[(4bR,6R,7R,8aR)-4b-ethyl-4b,5,6,7,8,8a,9,10-octahydro-6,7-dihydroxy-6-methyl-7-phenyl-2-phenanthrenyl]oxy)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 645397-94-0 HCPLUS
 CN 2,3-Phenanthrenediol, 4a-ethyl-1,2,3,4,4a,9,10,10a-octahydro-3-methyl-2-phenyl-7-[4-(1H-tetrazol-5-yl)propoxy]-, (2R,3R,4aR,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 645397-95-1 HCPLUS
 CN 2,3-Phenanthrenediol, 4a-ethyl-1,2,3,4,4a,9,10,10a-octahydro-3-methyl-2-phenyl-7-[4-(1H-tetrazol-5-yl)butoxy]-, (2R,3R,4aR,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 645397-96-2 HCPLUS

Absolute stereochemistry.




RN 645398-00-1 HCPLUS
 CN 2,3,7-Phenanthrenetriol, 4a-ethyl-1,2,3,4,4a,9,10,10a-octahydro-3-methyl-2-(4-methylphenyl)-, (2R,3R,4aR,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 645398-01-2 HCPLUS
 CN 2,3,7-Phenanthrenetriol, 4a-ethyl-1,2,3,4,4a,9,10,10a-octahydro-3-methyl-2-(1E)-1-propenyl-, (2R,3R,4aR,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.




RN 645398-02-3 HCPLUS
 CN 2,3,7-Phenanthrenetriol, 2,4a-diethyl-1,2,3,4,4a,9,10,10a-octahydro-3-methyl-, (2S,3R,4aR,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L4 ANSWER 2 OF 2 HCPLUS COPYRIGHT 2006 ACS on STN (Continued)
 CN Acetamide, N-(3-cyanopropyl)-2-[(4bR,6R,7R,8aR)-4b-ethyl-4b,5,6,7,8,8a,9,10-octahydro-6-methyl-7-phenyl-2-phenanthrenyl]oxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 645397-97-3 HCPLUS
 CN 2,3,7-Phenanthrenetriol, 2-ethenyl-4a-ethyl-1,2,3,4,4a,9,10,10a-octahydro-3-methyl-, (2R,3R,4aR,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 645397-98-4 HCPLUS
 CN 2,3,7-Phenanthrenetriol, 4a-ethyl-1,2,3,4,4a,9,10,10a-octahydro-3-methyl-2-(1-methylethyl)-, (2R,3R,4aR,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 645397-99-5 HCPLUS
 CN 2,3,7-Phenanthrenetriol, 4a-ethyl-1,2,3,4,4a,9,10,10a-octahydro-3-methyl-2-(2-propynyl)-, (2R,3R,4aR,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 645398-03-4 HCPLUS
 CN 2,3,7-Phenanthrenetriol, 4a-ethyl-1,2,3,4,4a,9,10,10a-octahydro-3-methyl-2-propynyl-, (2S,3R,4aR,10aR)- (9CI) (CA INDEX NAME)




RN 645398-04-5 HCPLUS
 CN 2,3,7-Phenanthrenetriol, 2-butyl-4a-ethyl-1,2,3,4,4a,9,10,10a-octahydro-3-methyl-, (2S,3R,4aR,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 645398-05-6 HCPLUS
 CN 2,3,7-Phenanthrenetriol, 2-butyl-4a-ethyl-1,2,3,4,4a,9,10,10a-octahydro-3-methyl-, (2S,3R,4aR,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 645398-05-6 HCPLUS
 CN 2,3,7-Phenanthrenetriol, 4a-ethyl-1,2,3,4,4a,9,10,10a-octahydro-3-methyl-2-(2-propenyl)-, (2S,3R,4aR,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 645398-06-7 HCPLUS
CN 2,3-Phenanthrenediol, 7-[(5-[(dimethylamino)methyl]-1,2,4-oxadiazol-3-yl)methoxy]-4a-ethyl-1,2,3,4,4a,9,10,10a-octahydro-3-methyl-2-phenyl-, (2R,3R,4aR,10aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



548/131
548/364


RN 645398-07-8 HCPLUS
CN 2,3-Phenanthrenediol, 4a-ethyl-1,2,3,4,4a,9,10,10a-octahydro-3-methyl-7-[(5-[(2-(4-morpholinyl)ethyl]-1,2,4-oxadiazol-3-yl)methoxy]-2-phenyl-, (2R,3R,4aR,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 645398-08-9 HCPLUS
CN 2,3-Phenanthrenediol, 7-[(5-[(2-(dimethylamino)ethyl]-1,2,4-oxadiazol-3-yl)methoxy]-4a-ethyl-1,2,3,4,4a,9,10,10a-octahydro-3-methyl-2-phenyl-, (2R,3R,4aR,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 645398-12-5 HCPLUS
CN Morpholine, 4-[[[(4bR,6R,7R,8aR)-4b-ethyl-4b,5,6,7,8,8a,9,10-octahydro-6,7-dihydroxy-6-methyl-7-phenyl-2-phenanthrenyl]oxy]acetyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 645398-13-6 HCPLUS
CN Piperazine, 1-[[[(4bR,6R,7R,8aR)-4b-ethyl-4b,5,6,7,8,8a,9,10-octahydro-6,7-dihydroxy-6-methyl-7-phenyl-2-phenanthrenyl]oxy]acetyl]-4-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 645398-14-7 HCPLUS
CN Acetamide, 2-[[[(4bR,6R,7R,8aR)-4b-ethyl-4b,5,6,7,8,8a,9,10-octahydro-6,7-dihydroxy-6-methyl-7-phenyl-2-phenanthrenyl]oxy]-N-(4-pyridinylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 645398-09-0 HCPLUS
CN 2,3-Phenanthrenediol, 4a-ethyl-1,2,3,4,4a,9,10,10a-octahydro-3-methyl-2-phenyl-7-[(5-[(2-(1-piperidinyl)ethyl]-1,2,4-oxadiazol-3-yl)methoxy]-, (2R,3R,4aR,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 645398-10-3 HCPLUS
CN Acetamide, N-[[3-[[{[(4bR,6R,7R,8aR)-4b-ethyl-4b,5,6,7,8,8a,9,10-octahydro-6,7-dihydroxy-6-methyl-7-phenyl-2-phenanthrenyl]oxy]methyl]-1,2,4-oxadiazol-3-yl)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 645398-11-4 HCPLUS
CN 2,3-Phenanthrenediol, 4a-ethyl-1,2,3,4,4a,9,10,10a-octahydro-3-methyl-7-[(5-[(1-methyl-1H-pyrrol-2-yl)methyl]-1,2,4-oxadiazol-3-yl)methoxy]-2-

Absolute stereochemistry.




RN 645398-15-8 HCPLUS
CN 2,3-Phenanthrenediol, 4a-ethyl-1,2,3,4,4a,9,10,10a-octahydro-3-methyl-7-[(4-morpholinyl)ethoxy]-2-phenyl-, (2R,3R,4aR,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 645398-16-9 HCPLUS
CN 2,3-Phenanthrenediol, 4a-ethyl-1,2,3,4,4a,9,10,10a-octahydro-3-methyl-2-phenyl-7-[(2-(1-piperidinyl)ethoxy)-, (2R,3R,4aR,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 645398-17-0 HCPLUS
CN 9(1H)-Phenanthrene, 4a-ethyl-2,3,4,4a,10,10a-hexahydro-2,3-dihydroxy-3-methyl-7-[(2-methyl-3-pyridinyl)methoxy]-2-phenyl-, (2R,3R,4aR,10aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 645398-18-1 HCPLUS
CN 2,3,7-Phenanthrenetriol, 4a-ethyl-1,2,3,4,4a,9,10,10a-octahydro-3-methyl-2-(2-pyridinyl)-, (2R,3R,4aR,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 645398-19-2 HCPLUS
CN 2,3,7-Phenanthrenetriol, 4a-ethyl-1,2,3,4,4a,9,10,10a-octahydro-3-methyl-2-(3-pyridinyl)-, (2R,3R,4aR,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 645398-21-6 HCPLUS
CN 2,3,7-Phenanthrenetriol, 4a-ethyl-1,2,3,4,4a,9,10,10a-octahydro-3-methyl-2-(4-pyridinyl)-, (2R,3R,4aR,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


CN 2,3-Phenanthrenediol, 7-[(5-[2-(1-azetidinyl)ethyl]-1,2,4-oxadiazol-3-yl)methoxy]-4a-ethyl-1,2,3,4,4a,9,10,10a-octahydro-3-methyl-2-(2-pyridinyl)-, (2R,3R,4aR,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 645398-27-2 HCPLUS
CN Acetamide, N-[3-[(4bR,6R,7R,8aR)-4b-ethyl-4b,5,6,7,8,8a,9,10-octahydro-6,7-dihydroxy-6-methyl-7-(2-pyridinyl)-2-phenanthrenyl]oxy]methyl]-1,2,4-oxadiazol-5-yl)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 645398-28-3 HCPLUS
CN 2,3-Phenanthrenediol, 7-[(5-[2-(dimethylamino)ethyl]-1,2,4-oxadiazol-3-yl)methoxy]-4a-ethyl-1,2,3,4,4a,9,10,10a-octahydro-3-methyl-2-(2-pyridinyl)-, (2R,3R,4aR,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 645398-23-8 HCPLUS
CN 2,3-Phenanthrenediol, 4a-ethyl-1,2,3,4,4a,9,10,10a-octahydro-3-methyl-7-((2-methyl-3-pyridinyl)methoxy)-2-(2-pyridinyl)-, (2R,3R,4aR,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




546/266

514/332


RN 645398-24-9 HCPLUS
CN Acetamide, 2-[(4bR,6R,7R,8aR)-4b-ethyl-4b,5,6,7,8,8a,9,10-octahydro-6,7-dihydroxy-6-methyl-7-(2-pyridinyl)-2-phenanthrenyl]oxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




CN Acetamide, 2-[(4bR,6R,7R,8aS)-4b-ethyl-4b,5,6,7,8,8a,9,10-octahydro-6,7-dihydroxy-6-methyl-10-oxo-7-(2-pyridinyl)-2-phenanthrenyl]oxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 645398-33-0 HCPLUS
CN 2,3,7-Phenanthrenetriol, 4a-ethyl-1,2,3,4,4a,9,10,10a-octahydro-3-methyl-2-(2-thiazolyl)-, (2R,3R,4aR,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 645398-34-1 HCPLUS
CN 2,3,7-Phenanthrenetriol, 2-(4,5-dimethyl-2-thiazolyl)-4a-ethyl-1,2,3,4,4a,9,10,10a-octahydro-3-methyl-, (2R,3R,4aR,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 645398-36-3 HCPLUS
CN 2,3,7-Phenanthrenetriol, 4a-ethyl-1,2,3,4,4a,9,10,10a-octahydro-3-methyl-2-(4-methyl-2-thiazolyl)-, (2R,3R,4aR,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 645398-37-4 HCPLUS
CN 2,3,7-Phenanthrenetriol, 4a-ethyl-1,2,3,4,4a,9,10,10a-octahydro-3-methyl-2-(5-methyl-2-thiazolyl)-, (2R,3R,4aR,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 645398-40-9 HCPLUS
CN Ethanone, 1-[(4bR,6S,7R,8aR)-4b-ethyl-4b,5,6,7,8,8a,9,10-octahydro-6,7-dihydroxy-6-methyl-7-phenyl-2-phenanthrenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 645398-47-6 HCPLUS
CN 2,3,7-Phenanthrenetriol, 4a-ethyl-1,2,3,4,4a,9,10,10a-octahydro-3-methyl-2-(4-methyl-2-thiazolyl)-, (2R,3S,4aR,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 645398-48-7 HCPLUS
CN 2,3-Phenanthrenediol, 4a-ethyl-1,2,3,4,4a,9,10,10a-octahydro-7-[(4-hydroxy-4-methylpentyl)oxy]-3-methyl-2-phenyl-, (2R,3R,4aR,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 645398-49-8 HCPLUS
CN 2,3-Phenanthrenediol, 4a-ethyl-1,2,3,4,4a,9,10,10a-octahydro-7-[(5-hydroxy-5-methylhexyl)oxy]-3-methyl-2-phenyl-, (2R,3R,4aR,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 645398-42-1 HCPLUS
CN 2,3,7-Phenanthrenetriol, 4a-ethyl-1,2,3,4,4a,9,10,10a-octahydro-7-(1-hydroxy-1-methylethyl)-3-methyl-2-phenyl-, (2R,3R,4aR,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 645398-43-2 HCPLUS
CN 2,3,7-Phenanthrenetriol, 4a-ethyl-1,2,3,4,4a,9,10,10a-octahydro-3-methyl-2-(phenylmethyl)-, (2R,3R,4aR,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 645398-46-5 HCPLUS
CN 2,3,7-Phenanthrenetriol, 4a-ethyl-1,2,3,4,4a,9,10,10a-octahydro-3-methyl-2-(2-thiazolyl)-, (2R,3S,4aR,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 645398-50-1 HCPLUS
CN 2,3,7-Phenanthrenetriol, 4a-ethyl-1,2,3,4,4a,9,10,10a-octahydro-3-methyl-2-(1-propynyl)-, (2R,3R,4aR,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 645398-51-2 HCPLUS
CN 2,3,7-Phenanthrenetriol, 4a-ethyl-1,2,3,4,4a,9,10,10a-octahydro-3-methyl-2-(1-propynyl)-, (2R,3R,4aR,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.




RN 645398-53-4 HCPLUS
CN 2,3,7-Phenanthrenetriol, 4a-ethyl-1,2,3,4,4a,9,10,10a-octahydro-2,3-dimethyl-, (2S,3R,4aR,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 645397-03-1
 RL: RCT (Reactant); SPP (Synthetic preparation); PREP (Preparation); RACT
 (Reactants or reagent)
 (Intermediate; preparation of octahydrophenanthrenols as glucocorticoid
 receptor modulators for treatment of inflammatory conditions)
 RN 645397-03-1 HCAPLUS
 CN 2,3-Phenanthrenediol, 7-[3-[(1,1-dimethylethyl)dimethylsilyl]oxy]propoxy)-
 4a-ethyl-1,2,3,4,4a,9,10,10a-octahydro-3-methyl-2-phenyl-,
 (2R,3R,4aR,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS
 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT